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Abstract
Since its discovery in the early 1990s, the orphan nuclear receptor SF-1 has been attributed a
central role in the development and differentiation of steroidogenic tissues. SF-1 controls the
expression of all the steroidogenic enzymes and cholesterol transporters required for
steroidogenesis as well as the expression of steroidogenesis-stimulating hormones and their
cognate receptors. SF-1 is also an essential regulator of genes involved in the sex determination
cascade. The study of SF-1 null mice and of human mutants has been of great value to demonstrate
the essential role of this factor in vivo, although the complete adrenal and gonadal agenesis in
knock-out animals has impeded studies of its function as a transcriptional regulator. In particular,
the role of SF-1 in the hormonal responsiveness of steroidogenic genes promoters is still a subject
of debate. This extensive review takes into account recent data obtained from SF-1
haploinsufficient mice, pituitary-specific knock-outs and from transgenic mice experiments carried
out with SF-1 target gene promoters. It also summarizes the pros and cons regarding the presumed
role of SF-1 in cAMP signalling.
Review
SF-1 general characteristics
A steroidogenic-tissue enriched factor
While trying to uncover the molecular mechanisms con-
trolling steroidogenic genes expression, two independent
research teams identified an AGGTCA (Ad4) motif in the
promoter region of these genes that was able to bind a
putative member of the nuclear receptor superfamily
[1,2]. This 53 kDa protein called Ad4BP (Adrenal 4 Bind-
ing Protein) or SF-1 (Steroidogenic Factor 1) is encoded
by a cDNA that was succesively cloned by the two teams
[1,3] and is specifically expressed in steroidogenic tissues
[1]. SF-1 shows high homology with the drosophila Ftz-F1
transcription factor, which controls fushi tarazu homeotic
gene expression [4]. The gene encoding SF-1, which is
conserved amongst metazoans, [5,6], was called Ftz-f1. It
encodes four different proteins ELP1, ELP2, ELP3 and SF-
1 by using alternative promoters and splicing. Although
ELPs are likely to play a repressive role on certain nuclear
receptors, [7,8], study of mice that were selectively ablated
for SF-1 has shown that it was the key activator of ster-
oidogenic endocrine function [9].
SF-1/Ad4BP: A nuclear receptor
Nuclear receptors usually display common features such
as a DNA-binding domain (DBD), a ligand binding
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SF-1, an orphan nuclear receptor Figure 1
SF-1, an orphan nuclear receptor. A- Canonical nuclear receptor and SF-1 structure comparison. AF1 : activation function 
1; DBD : DNA binding domain; LBD : ligand binding domain; AF2 : activation function 2. SF-1 does not harbor a classical AF-1 
domain. B- SF-1 functional domains. Zn I and Zn II : zinc fingers of the DBD; Ftz-F1 : Ftz-F1 box ; NLS : nuclear localization sig-
nal ; P-rich : proline-rich region ; FP : functional region encompassing the Ftz-F1 box and the proline-rich region ; pAF : proxi-
mal activation function ; pRD : proximal repression domain ; H1 : helix 1 of the LBD ; dRD : distal repression domain; AF2 AH 
: activation function 2 activation hexamer; S203 * serine at position 203, implicated in SF-1 responsiveness to the MAPK path-
way. Factors interacting with SF-1 that have allowed delineation of the functional domains are shown. Their interaction sites 
are figured by the grey bars.Nuclear Receptor 2003, 1 http://www.nuclear-receptor.com/content/1/1/8
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domain (LBD) and two activation domains, amino-termi-
nal AF-1 (activation function 1) and carboxyterminal AF-
2, whose activity is normaly dependent on the presence of
a ligand [10] (figure 1A). In all the species studied so far,
SF-1 harbors a classical DBD characterized by two Cys2-
Cys2 zinc fingers in the N-terminal region [11]. However,
as opposed to a majority of nuclear receptors, SF-1 binds
DNA as a monomer, in a manner reminiscent of NGFI-B
(Nur 77), ROR or LRH-1/CPF binding [10,12,13]. This
binding is stabilized by an A box or Ftz-F1 box which rec-
ognizes nucleotides flanking the AGGTCA nuclear recep-
tor core binding sequence on its 5' side (figure 1B). This
protein domain defines the binding specificity of a
nuclear receptor, as a function of its responsive element
[12,14]. The role of A box in SF-1 activity is illustrated by
a human mutation that results in sex reversal and adrenal
failure [15]. Nuclear receptors usually shuttle from the
cytoplasm where they bind their cognate ligands to the
nucleus where they activate transcription. This shuttling is
dependent on nuclear localisation signals (NLS). One
NLS is present on SF-1, downstream of the DBD (amino
acids 89 à 101). It is required for transcriptional activity
[14]. Although SF-1 harbors a putative LBD highly con-
served across species, it is classified as an orphan receptor
because no bona fide SF-1 ligand was identified so far
[16,17]. Recent experiments show that SF-1 LBD helices 1
and 12 can adopt an active conformation independently
of a ligand, in response to phosphorylation of a serine res-
idue at position 203 [18]. A conserved AF-2 domain that
recruits coactivators, is present in SF-1. It is necessary but
not sufficient for SF-1 transcativating activity [14,19–21].
In a majority of nuclear receptors, the AF-2 domain coop-
erates with the constitutive amino-terminal AF-1 domain
in order to activate transcription. Such N to C interactions
are essential for ligand-activated nuclear receptors func-
tion such as PPARγ [22] or AR [23,24]. SF-1 amino-termi-
nal region upstream of the DBD is very short and does not
possess a classical AF-1. In fact SF-1 AF-2 cooperates with
two activating domains downstream of the DBD. The
proximal activation domain (pAF: proximal activation
function) overlapping the hinge region and helix H1 of
the putative LBD (amino acids 187–245) is required for
maximal SF-1 activity with the coactivator SRC-1. It har-
bors a serine residue at 203, the phosphorylation of which
is essential for SF-1 activity [18,20,25]. The FP region
(amino acids 78 to 172), composed of the Ftz-F1 box and
of a proline-rich region, interacts with c-jun and TFIIB for
maximal activity [14].
SF-1 expression sites
As expected from its function as an essential regulator of
steroidogenesis, SF-1 is expressed in the testes and ovaries
as early as their anlages appear (figure 2). In the ovary SF-
1 expression rapidly decreases during development and
increases after birth [26–28]. Though the placenta is a
major steroid producing tissue during pregnancy, it only
shows slight SF-1 expression, detected by RT-PCR [29],
but not by in situ hybridisation [30] nor by northern-blot
[31]. Moreover, SF-1 knock-out mice do not show placen-
tal development nor placental steroid synthesis defects
[29]. Ben-Zimra et al. have confirmed that SF-1 is dispen-
sable in the placenta by showing that AP2 can substitute
for SF-1 to induce P450scc expression in this tissue [32].
SF-1 expression has also been detected in the pituitary
anlage, in the precursors of gonadotrope cells that control
reproductive function and in the ventro-medial hypotha-
lamus (VMH) which regulates the gonadotrope axis as
well as some aspects of metabolism [33–35]. At last, SF-1
has also been detected in skin [36] where it is associated
to steroidogenic enzymes [37–39] and in the spleen
[31,40].
SF-1 developmental expression pattern
Adrenals and gonads
SF-1 expression during development has been studied by
in situ hybridization, immunohistochemistry and more
recently with a transgenic mice line expressing the GFP
reporter gene under the control of SF-1 regulatory regions.
Gonads and adrenals are derived from a common precur-
sor, the adrenogenital primordium (AGP), located
between the coelomic epithelium of the urogenital ridge
and dorsal aorta. AGP is evidenced as early as 11.5 days of
embryonic development in rat [28] and as early as E9
(embryonic day 9) in mouse [26] (figure 2). In mouse,
adrenals and gonads anlages progressively individualize
from E9.5 to E10.5 and are perfectly distinct at E13. Pri-
mordial germ cells reach the sexually undetermined
gonadal anlage by E10. After E11.5-E12, the bipotent
gonad differentiates in testis (when Sry is expressed) or in
ovary. Adrenal primordium is colonized at E11.5 by nerve
cells that will later form the medulla. The cortex and
medulla are perfectly distinct at around E16-E16.5
[26,28]. Functional zonation of the cortex is then estab-
lished progressively. P450 aldosterone synthase express-
ing cells are found scattered throughout the cortex at E16
in rat and localize to the gland periphery by E19. Mean-
while, P450-11β expressing cells prolipherate and localize
in the future zonae fasciculata and reticularis [41].
SF-1 is detected at E9 in the AGP in mouse (E11.5 in rat).
At the time when gonadal and adrenal primordia individ-
ualize SF-1 is expressed in both cell populations and
remains expressed at the same level throughout adrenal
development. When cortex and medulla separate, SF-1
expression localizes to the cortical regions [26,28]. After
E18.5 and until 6 dpp (days post partum), SF-1 is hardly
detectable in mouse adrenals, and reaches fœtal
accumulation levels at 10 dpp [42]. This can be correlatedNuclear Receptor 2003, 1 http://www.nuclear-receptor.com/content/1/1/8
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to the postnatal stress hypo-responsive period, whose bio-
chemical basis is still unclear [43].
In the sexually undetermined gonad, SF-1 expression is
high until E12.5. It disappears in the ovary until E18.5
and increases thereafter [26]. In female rat maximum
accumulation is observed after 7 dpp concomitantly with
increases in the number of steroidogenic theca cells [27].
In the testis, SF-1 expression remains elevated during the
whole gestation and localizes in both steroidogenic Ley-
dig cells and Sertoli cells that surround seminiferous
tubules at E15 [26]. In rat testis, expression is maximal at
around 7 dpp and then decreases through to adulthood
when SF-1 accumulation is markedly reduced in Sertoli
cells [27]. Data regarding SF-1 expression in human ster-
oidogenic tissues are incomplete. Gonadal primordium
appears in the urogenital ridge at around 32 dpo (days
post ovulation), concomitantly with SF-1 expression, and
is sexually determined at 44 dpo, when SF-1 expression
markedly decreases in the ovary [44,45]. Adrenal develop-
ment in primates largely differs from what is observed in
rodents. During the major part of in utero life, adrenals are
composed of a large fœtal zone (80 to 90% of total vol-
ume) characterized by strong outgrowth and high steroid
producing capacities (mainly DHEA-S). This zone is sur-
rounded by a transitional zone, which produces cortisol
and that will later become the zona fasciculata. In turn,
transitional zone is itself surrounded by the definitive
zone, the embryonic equivalent to the zona glomerulosa.
After birth, fœtal zone regresses and the cortex acquires its
definitive structure [46]. SF-1 is expressed as soon as adre-
nal differentiates at 33 dpc (days post coïtum), at a higher
level than what is observed in undetermined gonads. SF-1
expression persists throughout fœtal development and
extends from foetal zone to definitive zone of the cortex
[47].
Adrenals and gonads development – SF-1 expression patterns Figure 2
Adrenals and gonads development – SF-1 expression patterns. The key events of steroidogenic tissues development 
in mice are shown. Molecular players in male sex (SRY, SOX9, SF-1, Dax-1) and female sex determination (Wnt4, Dax-1) are 
shown. Dax-1 function in sex determination is still unclear. Abreviations : E, embryonic day; dpc, days post coïtum ; dpp, days 
post partum; dpo, days post ovulation. SF-1 levels of expression are schematically presented below the time scale.Nuclear Receptor 2003, 1 http://www.nuclear-receptor.com/content/1/1/8
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Hypothalamus and pituitary
In adult mice, SF-1 is expressed in the ventro-medial
hypothalamus [34,35,48,49] and in the pituitary [33].
During development, SF-1 is first expressed in the dien-
cephalon at E12.5, and in the forming hypothalamus
between E14.5 and E17 [26]. It is also expressed in the
pituitary at E13.5-E14.5 where it preceds the transcripts
for LHβ and FSHβ [33]. In adults, expression is restricted
to gonadotrope cells that produce LH [33,34]. Although
the VMH is implicated in the regulation of sexual func-
tions, there is no dimorphism of SF-1 expression in this
tissue in adult mice [35].
SF-1 knock-out
Gonads and adrenals
The SF-1 and ELP isoforms were knocked-out in mice by
three teams simultaneously [29,34,50]. Homozygous
knock-out offsprings are observed in normal proportions
at birth, but die by eight days because of acute glucocorti-
coid and mineralocorticoid deficiency. Corticosterone
concentrations are very low and correlate with a marked
increase in plasma ACTH, confirming primary adrenal
failure and normal function of the pituitary corticotropes,
in the absence of negative feedback by glucocorticoids
[9,50]. Corticosteroid injections allow survival of knock-
out mice [9]. Homozygous knock-outs also show female
external genitalia, regardless of their genetic sex. Internal
observation of SF-1 ablated mice shows a complete lack of
adrenal glands and gonads and a persistence of Müllerian
ducts, regardless of the genetic sex [29,50]. Absence of tes-
tes in homozygous mutant male mice precludes MIS
(müllerian inhibiting substance) and androgen produc-
tion, which probably accounts for the observed pheno-
types. It is noteworthy that the abnormalities observed at
birth are not observed during precocious development.
Indeed, at E10.5, when sex determination has not yet
occured, the bipotential gonad is normal and colonized
by primordial germ cells in knock-out animals. However
at E12-E12.5, when sex determination normally occurs,
mutant mice gonads regress by apoptosis. The adrenal pri-
mordium also forms and progressively regresses at E11.5
[50]. Selective ablation of SF-1 but not of the ELP1-3 tran-
scripts resulted in the same phenotypes, demonstrating
the essential role of SF-1 in their etiology [9].
Altogether, these results show that SF-1 is indeed required
for differentiation and maintenance of the primordia for
adrenals and gonads, but that its presence is not required
for their early formation. The mechanisms underlying the
complete degeneration of the primordia are largely
unknown.
VMH and pituitary
SF-1 is normally expressed in the VMH and pituitary. The
histological appearance and physiology of both tissues
have been studied in knock-out animals. SF-1 -/- adult
mice neither express LHβ nor FSHβ, two markers of pitui-
tary gonadotrope cells, and do not show the characteristic
structures of the VMH [33–35,51,52]. These are present at
E17 but progressively regress thereafter, an observation
reminiscent of the situation in the gonads and adrenals
[35]. The cause of the absence of gonadotropins in gona-
dotrope cells is not clear. Absence of GnRH in SF-1 -/-
mice is not probable, as hypothalamic GnRH-producing
neurons are present and normally deliver it to the medial
eminence of the pituitary [35,53]. Pituitary-specific abla-
tion of SF-1 confirms the pituitary origin of the absence of
gonadotropins. Indeed these animals show the same
gonadotrope defects though their VMH is perfectly nor-
mal [53–55]. A direct effect of SF-1 in the pituitary is thus
probable, especially when considering that it is able to
control the in vitro expression of LH, FSH and GnRH
receptor [56–63]. However, although GnRH receptor is
not detected in knock-out mice [33,53], supra-physiologic
doses of GnRH are able to induce LH and FSH expression
through an unknown SF-1-independent mechanism
[35,53].
Primary consequences of SF-1 ablation at the level of pitu-
itary and hypothalamus have secondary consequences in
their target organs. Indeed, pituitary-specific knock-out
mice show marked hypogonadism which is characterized
by a 95% decrease in male and female gonad mass and
absence of sexual maturation, resulting in sterility
[35,53,54]. However, hypoplastic gonads have normal
morphology of immature gonads, indicating that their
precocious determination and differentiation normally
occur. This phenotype, which is equivalent to the pheno-
type of gonadotropes-ablated mice [64], can be reversed
by PMSG injection, indicating that this is indeed gonado-
tropins absence which is responsible for gonadal hypopla-
sia in pituitary-specific knock-outs [53]. This is confirmed
by observation of an attenuated gonadal phenotype in
mice with a pituitary-specific SF-1 hypomorphic allele
[55].
Lesions of the ventro-medial hypothalamus obtained by
stereotaxic surgery induce hyperphagia and obesity, sug-
gesting that the VMH could participate to satiety and feed-
ing control [65]. It is noteworthy that SF-1 -/- mice that are
maintained by adrenal transplantation, develop marked
obesity after 8 weeks. Around 6 months, their body mass
is nearly twice as wild type and this is correlated to a
marked increase in adipose tissue. Although the molecu-
lar basis for such a phenotype is not known, obesity seems
to be correlated to a decrease in daily exercise observed as
early as 7 weeks [52]. These results confirm that the VMH
may be implicated in the etiology of certain obesity phe-
nomenons, and suggest that SF-1 may have broader roles
in metabolism control.Nuclear Receptor 2003, 1 http://www.nuclear-receptor.com/content/1/1/8
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Collectively, these data indicate that SF-1 is required for
the differentiation of gonadotrope cells of the pituitary
and of the ventro-medial hypothalamus. Its presence does
not seem to be required for formation of the VMH of
which the anlage is present in knock-out mice, but may
participate to its maintenance during developement.
Spleen
The discovery that SF-1 is expressed in the spleen raises the
question of its potential role in non-steroidogenic periph-
eral tissues. SF-1 ablation induces defects in the establish-
ment of splancnic vascularization as well as defects in
erythropoïesis, although most hematopoïetic cell lines are
correctly matured and differentiated [40]. Whether SF-1
could be implicated in the vascularization of other tissues
such as the adrenals or gonads is an interesting question.
A defect in the formation of the endothelium could at
least in part, be responsible for the involution of gonadal
and adrenal primordia in knock-out mice. It is notewor-
thy that a steroidogenic tissue-specific endothelial growth
factor - EG-VEGF - has recently been identified [66]. A
potential implication of SF-1 in EG-VEGF or EG-VEGF
receptor expression has not been studied so far.
Human mutations of SF-1 : A comparison with murine 
phenotypes
Three SF-1 mutations have been described in humans so
far. Heterozygous G35E mutation which is located in the
first zinc finger of the DBD induces complete sex reversal
of the 46XY affected individual, which is associated to
major adrenal insufficiency [67]. Heterozygous R255L
mutation, located in the hinge region, induces bilateral
adrenal agenesis, but does not impair ovarian develop-
ment of the 46XX patient [68]. Homozygous R92Q muta-
tion which alters the A box of SF-1 is responsible for right
adrenal agenesis, left adrenal hypoplasia and sex reversal.
Both the parents and sister of the affected individual are
heterozygous for the mutation and do not show striking
phenotypes [15]. All these mutations affect SF-1 binding
and transactivating capacities without altering its accumu-
lation. Mutations that result in a phenotype when hetero-
zygous, completely abrogate SF-1 transactivating capacity
in cell transfection [67,68]. As the resulting proteins have
no dominant-negative effect, the drastic phenotypes
observed in heterozygotes, suggest that SF-1 works as a
dosage-sensitive protein in vivo [67,68]. This is consistent
with the absence of phenotype of heterozygotes bearing
the R92Q mutation which only slightly alters SF-1 trans-
activating properties in vitro [15]. These results prompted
investigators to study the effects of SF-1 haploinsuffi-
ciency in mice. Although not as obvious as in humans,
heterozygous SF-1 knock-out results in adrenal hypopla-
sia in both male and female mice at E15.5. After birth,
adrenal hypoplasia is associated to zona fasciculata hyper-
trophy as well as a marked decrease in corticosterone
response to stress or feeding, although basal corticoster-
one is unchanged. It's noteworthy that conserved basal
levels are correlated to increased StAR and MC2R tran-
scripts, indicating that factors other than SF-1 can regulate
StAR and MC2R transcription, at least in haploinsufficient
mice [69]. Collectively, these results show that SF-1 acts as
a dosage-sensitive factor for the proper differentiation and
function of the adrenal cortex in both mouse and human.
It is more difficult to put together human and murine
gonadal phenotypes resulting from SF-1 mutation.
Mutant 46XY heterozygous (G35E) or homozygous
(R92Q) individuals show complete sex reversal character-
ized by poorly differentiated hypoplastic gonads and
Müllerian duct persistence [15,67]. These observations
confirm the essential role of SF-1 for testes differentiation
and Müllerian duct regression. On the contrary, a 46XX
heterozygous woman bearing the R255L mutation does
not show significant ovarian dysfunction. The hetero-
zygous state of the mutation may account for the absence
of ovarian phenotype. However, the complete adrenal
agenesis observed in this patient argues against such an
explanation [68]. LRH-1 is a close homologue to SF-1
which is overexpressed in the liver where it participates to
bile acids synthesis control by binding to SFRE-like
sequences [70]. It is important to consider that LRH-1 is
highly expressed in the ovaries of humans and rodents
where it may control the promoter activity of steroid
hydroxylase genes [71–73] and to a much lesser extent in
the adrenal cortex [42,73]. The high level of LRH-1 expres-
sion in the ovaries may thus account for redundancy,
masking the effect of SF-1 mutation. However, as hetero-
zygous SF-1 mutant mice show non-characterized ovarian
hypoplasia, species-specific mechanisms in ovarian differ-
entiation may be envisaged [69]. Though, one must keep
in mind that SF-1 null mice do not express SF-1 protein
whereas human patients still express the mutant version
that may contribute to the displacement of subtle equilib-
riums. At last, another possible explanation is that pitui-
tary gonadotrope function is not affected in humans
whereas it is abolished in mice. The strong ovarian pheno-
type in mice would then result from a combination of
central and primary defects. Gonad-specific SF-1 knock-
out may provide important information regarding this
issue.
Despite interspecies differences, observations in SF-1 null
mice and human mutants clearly show a key role for SF-1
in the development and / or differentiation of steroidog-
enic tissues and their central regulators (hypothalamus
and pituitary) (table 1). Tissue and cell-specific SF-1
knock-outs should be valuable models to differentiate
between primary effects of SF-1 ablation in steroidogenic
tissues and effects resulting from central nervous system
defects.Nuclear Receptor 2003, 1 http://www.nuclear-receptor.com/content/1/1/8
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A role for SF-1 in cell differenciation and proliferation?
All the data presented above do not allow to distinguish
between SF-1 implication in cell fate determination / dif-
ferentiation and proliferative effects. ES cells stably
expressing SF-1 are able to morphologically differentiate
into steroidogenic cells that express the rate-limiting
P450scc enzyme. P450scc expression and subsequent pro-
gesterone production are stimulated by cAMP. This activa-
tion is prevented by cycloheximide, indicating that it
requires de novo synthesis of factors that are absent from
unstimulated cells. At last, P450scc induction is inde-
pendent of SF-1 transactivating properties as measured by
activation of a reporter gene, under the control of a SF-1
responsive element. This suggests that SF-1 is required for
differentiation of ES cells and for the expression of factors
that are implicated in cAMP responsiveness, although it
doesn't directly participate in the latter [74].
After unilateral adrenalectomy, the remaining adrenal is
able to compensate for adrenal defect by engaging in
hypertrophy and hyperplasia (compensatory growth),
through a regulatory loop implicating the VMH. Beusch-
lein et al. have shown that in SF-1 +/- mice, there was no
compensatory growth in the remaining adrenal following
unilateral adrenalectomy, indicating that SF-1 was proba-
bly required for hyperplasia and hypertrophy to occur
[75]. This phenotype is correlated to absence of overex-
pression of AsP, an adrenal-specific protease which
cleaves pro-γ-melanotropin into an adrenal mitogenic
peptide [76], and of PCNA, a cell proliferation marker
[77], in response to unilateral adrenalectomy. This shows
that beyond its role in cell differentiation, SF-1 may also
be crucial for cell proliferation in steroidogenic tissues.
SF-1 target genes
Genes implicated in steroidogenesis
SF-1 was initially identified for its capacity to interact with
and activate the promoters of the steroidogenic enzymes
P450SCC, CYP11B1 and CYP21 [1,2], through the con-
sensus AGGTCA sequence. In the last ten years, transient
transfection studies have shown that SF-1 participates to
the expression of all steroidogenic enzymes in the adrenal
cortex and gonads (table 2). In any case except for
CYP11B2 which synthesizes aldosterone in the zona
glomerulosa [78], SF-1 activates basal expression of these
genes. Because of its tissue-restricted pattern of expres-
sion, SF-1 is obviously a key factor in the tissue-restricted
expression of steroidogenic enzymes. Its implication in
their cAMP responsiveness is still a subject of debate. At
least, cAMP-sensitive promoter regions often overlap with
SF-1 responsive elements the mutation of which alters
cAMP responsiveness [47,78–86]. These experiments
indicate that SF-1 may be required to mediate cAMP
responsivenes, but they do not show that it is sufficient for
this process. Indeed, inside P450scc promoter, a proximal
SF-1 responsive element (-40) is solely required for basal
activity, whereas a distal site (-1600) is required for hor-
monal sensitivity in vivo [79]. If SF-1, was intrinsically a
mediator of cAMP signaling, it would be difficult to
understand how it would behave differently from one site
to another. This underlines the essential role of the DNA
context of the SF-1 responsive element in its ability to
transduce activation of the cAMP pathway to promoters.
Besides steroidogenic genes, SF-1 is also able to modulate
cholesterol delivery to steroidogenic reactions, by control-
ling expression of the HDL-receptor SR-BI, of intracellular
cholesterol transporter SCP2 [87], and of StAR which
transfers cholesterol from the outer to the inner mito-
chondrial membrane [88]. SF-1 can also stimulate de novo
cholesterol synthesis in steroidogenic tissues through acti-
vation of HMG-CoA synthase, irrespective of intracellular
cholesterol concentrations [89]. SF-1 also controls expres-
sion of the receptors for ACTH and FSH, the hormones
that stimulate adrenal and gonadal steroidogenesis,
respectively. Our group has also demonstrated that SF-1
could also control akr1-b7 expression in vitro and in vivo.
This gene whose expression is controlled by ACTH in the
Table 1: Phenotypes resulting from genetic ablation or mutations of the orphan nuclear receptor SF-1.
Organism Mouse Human
Genotype SF-1 -/- SF-1 +/- SF-1 m/+ ou SF-1 m/m
Adrenal - Agenesis - Histological defects
- Hyporesponse to stress
- Compensatory growth defects
- Insufficiency (agenesis or dysgenesis)
Testis - Agenesis
- Sex reversal
- Sex reversal
Ovary - Agenesis - Normal
VMH - Agenesis
- Obesity caused by absence
of the VMH (8 weeks)
Pituitary - Defects of gonadotrope cellsNuclear Receptor 2003, 1 http://www.nuclear-receptor.com/content/1/1/8
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adrenal cortex, encodes a protein which detoxifies isoc-
aproaldehyde, produced by the cleavage of cholesterol
through action of P450scc [42,90–93]. It is noteworthy
that a new class of genes coding proteins able to reduce
toxic side-effects of steroidogenic reactions, is emerging.
Indeed, expression of superoxyde-dismutase 2 (SOD2),
which protects adrenal cells against free radicals generated
during steroidogenesis, is also controlled by ACTH [94].
However Chinn and colleagues have not studied the role
of SF-1 in the control of SOD2 expression in adrenocorti-
cal cells. Altogether, these results confirm the major role
of SF-1 as a key activator of steroidogenesis. However,
most of these studies rely upon transient transfections in
heterologous cells that do not necessarily represent a good
model enough for studying the role of SF-1 on gene tran-
scription. As SF-1 null mice completely lack steroidogenic
tissues, the easiest alternative to study these mechanisms
in a physiological context, is to generate transgenic mice
harboring wild-type or mutant constructs of the promoter
being studied.
Genes of the central nervous system
Analyses of SF-1 null mice have shown the key role of this
factor for the establishment of the hypothalamus-pitui-
tary-adrenal and hypothalamus-pituitary-gonadal axes.
Neuronal NO synthase participates to the secretion of
GnRH, the neuropeptide responsible for the synthesis and
secretion of LH and FSH by pituitary [95]. Although SF-1
Table 2: A summary of SF-1 target genes. (After Hammer and Ingraham, Ref. [11], updated) The cell types where the studies were 
conducted are presented. Studies in vivo using transgenic approaches are specified. Basal: SF-1 is required for basal promoter activity 
of the gene being studied. Induction: SF-1 participates to the cAMP responsiveness of the gene. A different induction signal is stated. 
N.D. SF-1 implication in the cAMP responsiveness was not determined. Lower case letters before the names of the promoters 
correspond to the species that were studied (h: human; r: rat; b: bovine; m: mouse).
Gene promoter Cell type /Transgenic technique Basal activity/induction by cAMP Bibliography
hP450scc Additive transgenesis, H-295 basal + induction [79,80]
rP450scc MA-10, rat granulosa basal [138,188]
bP450scc Y1, bovine luteal cells, COS1 basal + induction [162]
h3β-HSD type II H295, HeLa basal + N.D. [189]
mCYP21 Y1 basal + N.D. [2,190]
hCYP11B1 Y1, H295 basal + induction [78,81]
bCYP11B1 Y1, I-10 (Leydig) basal + induction. [191,192]
hCYP17 H295 basal + induction [47,82,183,185]
bCYP17 Y1, COS-1 basal + induction [83,84]
rCYP19 R2C, H450, Y1 basal + induction [86,164,193,194]
hCYP19 Bovine luteal cells basal + induction [85]
h/mCYP11B2 H295 inhibition by SF-1 [78]
AKR1-B7 Additive transgenesis, HeLa, CV-1 basal [42,90–92]
HDL-R/SR-BI Y1, HTB9 basal + induction [195–198]
SCP2 Y1, HTB9 basal + induction [199]
hStAR Y1, BeWo, H295 basal + induction [200–203]
mStAR Y1, MA-10 basal [112]
rStAR Y1, HTB9 (human bladder carcinoma) basal + induction [204]
bStAR HeLa basal + induction [205]
HMG-CoA reductase CV-1, MA-10 basal + N.D. [89]
hMC2R H295-R basal + induction [206,207]
mMC2R Y1 basal + N.D. [208]
mFSH-R HEK-293 basal [60]
rFSH-R JEG-3 basal + inhibition of PKA induction [209]
rLH-R Granulosa basal inhibition [210]
R-GNRH αT3-1 basal [61,62,211,212]
LHβ Additive transgenesis, LβT2, αT3-1, basal + induction by GnRH in association with Sp1, 
EGR-1 and Ptx1
[58,156,157,213,214]
hαGSU LβT2 gonadotropes basal + induction by GnRH [215]
Neuronal mNOS αT3-1, NIH3T3 basal [96]
b-ocytocin TM4 basal [216,217]
PRL-R MLTC (Leydig) basal [218]
MIS Knock-in mice, HeLa, JEG-3 basal [104,107,108]
DAX-1 Additive transgenesis, H295, JEG-3 basal [187,219–221]
RLF/INSL3 MA-10, HeLa, mLTC-1, HEK293 basal [109,110]
α-inhibin tsa, GRMO2 granulosa basal + induction [163]Nuclear Receptor 2003, 1 http://www.nuclear-receptor.com/content/1/1/8
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knock-out mice do not show obvious GnRH secretion
defect [35,53], SF-1 is able to control neuronal NO syn-
thase gene transcription in vitro [96]. This raises the ques-
tion of a more general role of NO in the etiology of the
phenotypes in null mice. Pituitary glycoproteins LH and
FSH are composed of a common subunit, αGSU, which is
associated to a β chain, specific to LH or FSH. Gonadotro-
pins production and secretion is controlled by GnRH
which activates Ca2+ and PKC pathways through its recep-
tor [97]. In vitro, SF-1 controls expression of the GnRH
receptor, αGSU and LHβ, but not of FSHβ. All these pro-
teins are absent from SF-1 -/- mice pituitaries suggesting
that SF-1 participates to their expression in vivo [53,54].
However, null mice treatment with supra-physiological
GnRH doses induces LH and FSH expression in the
absence of detectable amounts of GnRH receptor [35,53].
Although the question of GnRH action in SF-1 null mice
is as yet unresolved, these surprising results shed light on
transcription factors other than SF-1, that may participate
to LH and FSH expression in vivo.
Genes implicated in sexual differentiation and sex determination
In mammals, male sex determination is triggered by the Y
chromosome-borne SRY gene. SRY activation in turn trig-
gers expression of SOX9 which stimulates MIS transcrip-
tion in Sertoli cells. This hormone from the TGF-β family,
is responsible for the regression of Müllerian ducts that
normally form oviducts, uterus and the upper third of the
vagina in females [98].
SF-1 expression in the urogenital ridge at E9.0 [26] pre-
cedes expression of SRY in pre-sertoli cells at E10.5 in
mouse [99,100]. SF-1 has recently been shown to regulate
human and porcine SRY expression. One SF-1 responsive
site at -327 is required for a modest activation of human
SRY promoter [101] whereas two sites are essential for
porcine SRY promoter activity in porcine genital ridge
cells [102]. Although the physiological relevance of such
an observation is not established yet, treatment of NT2/
D1 embryonic carcinoma cells with cAMP induces SF-1
phosphorylation that prevents its binding to the SRY pro-
moter, thus downregulating human SRY expression [101].
Nonetheless, it is noteworthy that residual SRY expression
is observed in SF-1 knock-out mice [103], suggesting that
SF-1 may not be essential for triggering SRY expression.
SF-1 and MIS are coexpressed in developing Sertoli cells
[104], and SF-1, in association with SOX9 [105], GATA-4
[106] and WT-1 [107] is able to stimulate MIS promoter
activity in transient transfections (figure 3). Male SF-1 null
mice show Müllerian duct persistence [29,34,50]. How-
ever, the absence of gonads in these animals does not
allow a conclusion on a direct effect of SF-1 to be drawn.
This difficulty was overcome by mutating the proximal SF-
1 responsive element of the MIS promoter by homolo-
gous recombination with the endogenous MIS locus. This
mutation reduces MIS accumulation albeit to an extent
which is insufficient to prevent Müllerian duct regression,
whereas when the SOX9 binding site is mutated by the
same procedure, there is Müllerian duct persistence in
male mice (figure 3). These results suggest that SOX9 trig-
gers MIS expression whereas SF-1 acts as a quantitative
regulator [108].
Gonadal descent is a process associated to male sexual dif-
ferentiation which is dependent on regression of the cra-
nial suspensory ligament and proliferation of the
gubernaculum specifically in males. The knock-out of the
Insl3/RLF gene, which codes a protein produced by Leydig
cells, results in a defect in testes descent. It is noteworthy
that SF-1, at least in vitro, is able to control RLF expression
through three responsive-elements [109,110]. Confirma-
tion of the role of SF-1 in testis descent via RLF should
come from observation of testes position in SF-1 +/- mice,
or of gubernaculum proliferation in null mice.
SF-1 target genes : unanswered questions
The number of SF-1 potential target genes is rapidly grow-
ing. However few studies are based on the in vivo demon-
stration that SF-1 responsive elements are indeed required
for putative target genes expression. Analysis of putative
target genes in SF-1 haplo-insufficient mice may confirm
the role of SF-1 in their expression. However, compensa-
tory mechanisms as those observed for StAR expression in
SF-1 +/- mice, may mask the effects of SF-1 dosage reduc-
tion [69].
The presence of gonadal and adrenal anlages in SF-1
knock-out mice and their rapid disappearance during
development suggests that SF-1 regulates genes that are
implicated in cell survival and/or proliferation. The
majority of known SF-1 target genes is responsible for the
maintenance of differentiated function rather than sur-
vival of steroidogenic tissues. Degeneration of steroidog-
enic tissues in null-mice is due to apoptosis [50]. It was
recently shown that glucocorticoids can protect glandular
tissues such as ovarian follicular cells against apoptosis
although they have a pro-apoptotic effect on hemat-
opoïetic cells [111]. As SF-1 controls the expression of
StAR [112] and P450scc [79], two enzymes that are indis-
pensable for glucocorticoids production, apoptosis in SF-
1 null-mice may be due to glucocorticoids defects. In fact,
this is rather unlikely because StAR [113] or P450scc [114]
genetic ablation results in histological defects of the
adrenals that are linked to progressive cholesterol accu-
mulation, but does not result in adrenal regression during
development.
POMC is the pituitary peptide that is cleaved to produce
ACTH, pro-γ-MSH and β-LPH. Interestingly, POMCNuclear Receptor 2003, 1 http://www.nuclear-receptor.com/content/1/1/8
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knock-out mice show defective adrenal development
[115]. The role of ACTH in trophic and mitogenic stimu-
lation of the adrenal cortex is still a subject of intense
debate [76,116,117]. The N-POMC(1–52) peptide,
derived by cleavage of pro-γ-MSH shows highly mitogenic
activity on adrenocortical cells. AsP, the adrenal-specific
protease which is responsible for its cleavage, and its cog-
nate receptor have been cloned recently. These are specif-
ically expressed in the outermost regions of the cortex and
the protease is required for Y1 cells growth [76,118]. An
important question is now to determine whether SF-1 reg-
ulates AsP and its receptor expression in the adrenal
cortex.
Control of SF-1 expression and activity
SF-1 activity on its target genes must be tightly controlled.
This can be achieved by ligands or cofactors (coactivators/
corepressors or transcription factors) or directly by modu-
lating expression of the nuclear receptor. In numerous
steroidogenic genes promoters, cAMP-responsive regions
overlap with SF-1 responsive elements. This chapter will
particularly address the complex issue of cAMP signalling
transduction through SF-1.
SF-1: still an orphan?
During the last decade, numerous orphan nuclear recep-
tors have been cloned without any known ligand. Some,
like LXR, FXR, PXR or CAR, have since been attributed a
ligand, whereas others like Nur77/NGFI-B, Nurr-1, LRH-1
or DAX-1, have no known ligand so far and seem to be
activated by other mechanisms [5,10]. 25-hydroxycholes-
terol, an hydroxylated cholesterol derivative is able to acti-
vate CYP21 promoter transcription in a SF-1 dependent
manner in heterologous CV-1 cells, indicating that it
could be a SF-1 endogenous ligand [119]. Nonetheless, in
steroidogenic MA-10 cells that naturally express SF-1,
both exogenous and endogenous 25-hydroxycholesterol
are unable to stimulate endogenous P450scc expression as
well as six SF-1-responsive reporter genes [16]. Collec-
tively, these results tend to prove that 25-hydroxycholes-
terol is not a bona fide ligand for SF-1 in steroidogenic
cells. This is confirmed by the ability of SF-1 LBD to adopt
an active conformation independently of any ligand [18].
Factors controlling SF-1 transcription
A small 90 bp SF-1 proximal promoter is specifically
expressed in adrenocortical cells in transient transfections.
This region encompasses an E-box (-87/-82), a Sp1
binding site (-30/-24) and a CAT box that binds CBF (-68/
-59) [120,121] (figure 4). If the role of the latter is not
MIS promoter Figure 3
MIS promoter. Binding sites for the transcription factors required for proper MIS expression are shown. Their position in 
human MIS promoter is indicated (hMIS). WT1 and Dax-1 are able to respectively stimulate or repress MIS promoter activity 
by interacting with SF-1 bound to its proximal responsive element. Effect of the mutation of the proximal SFRE or SOX9 
responsive element introduced by knock-in in mice on Müllerian ducts regression is indicated. Abreviations : Sox BS, SOX fac-
tors binding site; SFRE, SF-1 responsive element.Nuclear Receptor 2003, 1 http://www.nuclear-receptor.com/content/1/1/8
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clearly demonstrated, transcriptional control of SF-1
expression at least requires the E-box which is conserved
in human and which is functional in both steroidogenic
and non-steroidogenic cells [120,122–124]. This element
is able to bind the ubiquitous USF factor contained within
pituitary αT3-1 cells, steroidogenic Y1 and JEG-3 cells, as
well as CV1 and HeLa cells [123]. None of these interac-
tions however, can account for tissue-restricted SF-1
expression. SF-1 itself is able to bind a site which is present
in its own first intron in rat and human genes (+156/
+163) [124,125] (figure 4). Whereas Nomura et al., [125]
have shown the role of this sequence for the expression of
a reporter gene in Y1 cells, or in response to SF-1 overex-
pression in heterologous CV-1 cells, Woodson et al., using
the rat gene and Oba et al., using the human gene, were
unable to obtain the same results in either steroidogenic
or non-steroidogenic cells [120,124]. However, it is worth
considering that some sequences contained within the
first intron might be required for SF-1 expression, though
their specificity is not yet established [124]. This is con-
firmed by the use of different lengths of SF-1 regulatory
regions and intragenic sequences in transgenic mice
[49,126]. SF-1 is expressed in the urogenital ridge as early
as E9.5 at similar levels in males and females. When sex
determination occurs between E10.5 and E12.5, SF-1
expression strongly decreases in the ovary until E18.5,
whereas it remains elevated in the testis. After birth,
expression rises in the ovary although it is reduced in
adult testis [26,27]. Pod-1/Capsulin is a transcription fac-
tor of the b-HLH family which is able to heterodimerize
with other factors of the family by binding to E-boxes (fig-
ure 4). It participates to kidney and lung differentiation
[127] and displays a sexually dimorphic pattern of expres-
sion in the gonad, which is reminescent of SF-1 gonadal
expression. However, Pod-1 is expressed in gonadal
regions where SF-1 is not expressed (i.e. coelomic epithe-
lial cells, peritubular myoid cells and epithelial-like cells).
In fact, it seems that Pod-1 may act as a repressor of SF-1
promoter activity through interaction with the previously
described E-box [128]. Sox9 and SF-1 are colocalized in
somatic cells of the testis and follow parallel expression
patterns during development [129]. They both participate
to transcriptional activation of the MIS promoter in males
[105]. Recent results show that Sox9 is able to induce SF-
1 expression in heterologous cells and that a Sox9 binding
site (-110/-104) is required for SF-1 expression in Sertoli
and Y1 cells [130] (figure 4). GATA-4 is also dimorphi-
cally expressed in the gonad. Whereas its expression is
high in the undetermined gonad it decreases as ovary dif-
ferentiation starts, although it is maintained in the testis.
This dimorphism may participate to the control of MIS
expression [131], but GATA-4 is also able to moderately
activate SF-1 expression via a conserved site at -177/-172
(figure 4). This activation is dependent on the cell type
and seems to be essentially restricted to Sertoli cells where
SF-1 participates to MIS expression [132]. Although most
elements required for SF-1 expression in steroidogenic tis-
sues are likely to be localized in the 5' flanking regions
and first intron of the gene, a GFP/SF-1 fusion, the expres-
sion of which is directed by a 50 kb BAC comprised of SF-
1 promoter, first exon and first intron, is not expressed in
pituitary gonadotropes [49]. Although a single transgenic
line was studied so far, this indicates that further down-
stream sequences might be required for pituitary expres-
sion. However, there is no mention of pituitary expression
in the work of Zubair et al., who used SF-1 regulatory
regions extending from the first intron to the seventh exon
[126]. Altogether, these data allow a better understanding
of SF-1 tissue-specific expression especially in the gonads
but do not establish a link between SF-1 transcription and
the cAMP signalling pathway.
Is SF-1 accumulation altered by cAMP pathway stimulations?
In vivo, SF-1 protein accumulation in the adrenals and
gonads is unchanged by a four weeks hypophysectomy in
rats [133]. However an eighty hours treatment of mice
with dexamethasone, induces a marked reduction of SF-1
mRNA accumulation in the adrenals [134], suggesting
that compensatory mechanisms may have masked the
effects of long term hypophysectomy on SF-1 accumula-
tion. Nonetheless, lipopolysaccharide treatment which
induces increases in circulating ACTH concentrations, has
no effect on SF-1 accumulation [134]. The problem is far
more complex in cell culture systems. Whereas numerous
papers show that SF-1 mRNA accumulation is unchanged
in Y1, MA-10, theca or bovine granulosa cells in response
to forskolin or PKA catalytic subunit overexpression
[135–138], one paper describes a slight increase in bovine
adrenocortical cells treated with ACTH [139]. At last, in
human granulosa cells [140] or in forskolin-treated Y1
cells, SF-1 protein accumulation increases independently
of an increase in its mRNA accumulation [137]. Based on
this observation, Aesoy et al. have proposed a post-trans-
lational model in which PKA could stabilize SF-1 protein
[137]. However, this was only demonstrated in a heterol-
ogous cell system overexpressing both SF-1 and the PKA
catalytic subunit. Interestingly, we have not been able to
obtain similar results with both Y1 and ATC-1 [141]
adrenocortical cell cultures treated with forskolin or
ACTH, respectively. Our unpublished data rather suggest
that SF-1 accumulates into cell nucleus in response to
cAMP, without a concomitant increase in overall protein
accumulation (Bruno Ragazzon, personal communica-
tion). This increase in SF-1 nuclear accumulation
correlates with increased SF-1 binding in gel shift experi-
ments (Christelle Aigueperse, personal communication).
Whatever the changes in SF-1 expression may be, simple
modulations of SF-1 accumulation are unlikely to account
for some SFREs being implicated in cAMP-responsiveness
while others only support basal promoter activity in vivoNuclear Receptor 2003, 1 http://www.nuclear-receptor.com/content/1/1/8
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[42,79]. This differential activity may be achieved by more
subtle mechanisms that control SF-1 activity, such as
interaction with other transcription factors and / or
cofactors.
SF-1 cofactors
Ligand-dependent nuclear receptors activate their target
genes transcription through interactions with coactivators
and/ or corepressors that link receptors to the transcrip-
tion machinery. Accordingly, SF-1 harbors an AF2 activa-
tion domain in its LBD (figure 1B). This motif (LLIEML,
consensus LLXXL) is necessary but not sufficient for trans-
activation [14,19–21] which also depends on two amino-
terminal regions of the protein, the FP region [14] and a
proximal activation domain [20,25]. SF-1 proteins bear-
ing mutations in their AF2 domain have dominant nega-
tive properties on CYP17 promoter activation by PKA in
Y1 cells. This suggests that SF-1 AF2 is implicated in the
transduction of the cAMP signal [83]. As ligand-activated
nuclear receptors, SF-1 interacts with numerous coactiva-
tors such as SRC1 [19,20], RIP140 [142], PNRC and
PNRC2 [143,144], hMBF1 [145], TIF2 [25], p/CIP [146]
and GCN5 [147]. These interactions, independent of an
exogenous ligand, are dependent on AF-2 and for some of
them, on proximal interaction domain integrity. Most of
these interactions are mediated by LXXLL motifs found on
coactivators. PNRC and PNRC2 are quite unique in that
they interact with SF-1 and other nuclear receptors
through SH3 proline-rich motifs [143,144]. None of these
coactivators is specific for SF-1 and none of them shows a
steroidogenic tissue-restricted pattern of expression.
Nonetheless, two of them may be required for integration
of the cAMP signalling (figure 5). TIF2 and p/CIP interact
with SF-1 through the AF-2 and proximal activation
domain [25,146]. Overexpression of TIF2 or p/CIP in het-
erologous or Y1 cells, stimulates transcription of a
reporter gene driven by four copies of a SF-1 responsive-
sequence of the bovine CYP17 promoter. However,
whereas p/CIP increases sensitivity to PKA overexpression
in the presence of SF-1, overexpression of the catalytic
subunit of the PKA inhibits potentiation of SF-1 activity
by TIF2, through a decrease in TIF2 protein accumulation
[146]. In a more physiological system, one might imagine
that on the sites where it participates to cAMP-responsive-
ness, SF-1 would preferentially associate to p/CIP,
whereas where it participates to basal promoter activity,
SF-1 would rather associate to TIF2. What could allow SF-
1 to choose between those two coactivators? Although the
sequence of the SF-1 responsive element may participate
to this choice, it is possible that adjacent transcription
factors, endowed with cAMP sensing capacity, may mod-
ulate cofactors recruitment by SF-1. This would allow
modulation of SF-1 activity in response to extra-cellular
signals.
DP103 is a DEAD-box protein which is highly expressed
in steroidogenic tissues (table 3). Although it has intrinsic
RNA helicase properties as other proteins of its family
[148], DP103 physically interacts with SF-1 through a
newly described repressive domain, located in the vicinity
of the proximal activation domain [149]. DP103 harbors
a C-terminal repression domain that by itself, represses
SF-1 activity. DP103 repressive function is independent of
its helicase activity and can decrease P450scc and P450c21
Schematic representation of SF-1 regulatory regions Figure 4
Schematic representation of SF-1 regulatory regions. A summary of the experimental results obtained with SF-1 regu-
latory regions in humans, rats and mice is presented. Cis elements are conserved across the three species. Numbering may 
vary from one species to another. Pod-1/Capsulin and USF bind to the same response element. USF activates SF-1 transcrip-
tion whereas Pod-1 is likely to repress it. Abreviations : GATA, GATA proteins response element; Sox BS, Sox proteins bind-
ing site; CAT, CAAT box; Sp1, Sp1 response element; Inr, initiator; SFRE, SF-1 responsive element; USF, upstream stimulatory 
factor; CBF, CAT box binding factor.Nuclear Receptor 2003, 1 http://www.nuclear-receptor.com/content/1/1/8
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promoter activity, inducing a significant reduction in pro-
gesterone production by Y1 cells [148]. One interesting
question is now to analyze whether DP103 is implicated
in the cAMP responsiveness of steroidogenic enzymes
genes.
Transcription factors associated with SF-1
Apart from interaction with bona fide cofactors, SF-1 also
interacts with numerous transcription factors (table 3)
that modulate its activity either by binding to adjacent
DNA sequences or by interacting with SF-1 without bind-
ing to DNA [106,107,150–152]. The regions of
interaction between SF-1 and other transcription factors
are rather broadly delineated. These can overlap with pre-
viously described regions such as AF-2 or the proximal
activation domain [14,160] but also extend to the DBD
[107,153] and LBD [107,154] or distal [152] and proxi-
mal [148] repression domains. These interactions result in
variable responses depending on the promoter or cell type
under experiment.
Presumed effect of the coactivators p/CIP and TIF2 on SF-1 transactivation Figure 5
Presumed effect of the coactivators p/CIP and TIF2 on SF-1 transactivation. (After Borud et al., Ref. [188]). In the 
absence of PKA, p/CIP and TIF2 potentiate SF-1 transcriptional activity. When SF-1 is associated to p/CIP, overexpression of 
PKA induces a marked increase in SF-1 transcriptional activity. On the contrary, PKA overexpression prevents TIF2-dependent 
potentiation of SF-1 activity. The decrease of TIF2 protein accumulation caused by PKA overexpression may explain these 
observations. SFRE : SF-1 responsive element.Nuclear Receptor 2003, 1 http://www.nuclear-receptor.com/content/1/1/8
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A first class of factors, illustrated by the studies on MIS and
LH-β promoters, encompasses proteins that will restrict
SF-1 target genes expression in a very narrow region of the
organism in a particular context. Indeed, the combinatory
interactions between SF-1, WT-1 [107], GATA-4
[106,150], SOX-9 [105,108] and DAX-1 [107] allow MIS
expression specifically by Sertoli cells of the male gonad,
just before regression of the Müllerian ducts (figure 3).
Also, this is an interaction between Egr-1, Ptx1 and SF-1
that allows expression of the LH-β subunit in pituitary
gonadotrope cells in response to GnRH stimulation [155–
159].
Another group of factors is more implicated in SF-1 target
genes response to external stimuli. Indeed, SF-1
interaction with TReP132 [160,161], Sp1 [153,162] or
CREB [86,163,164] allows recruitment of the CBP/p300
coactivator which interconnects multiple cell signalling
pathways [165]. This may participate to the cAMP respon-
siveness of some SF-1 target genes.
At last, a third interaction group allows repression of SF-1
activated genes. DAX-1 is the paradigm of such repressors.
It encodes a peculiar nuclear receptor devoid of a classical
DNA binding domain, which is replaced by three-and-a
half repeats of an alanine and glycine-rich motif
[166,167]. DAX-1 overexpression subsequent to Xp21
duplication, induces male to female sex reversal in
humans [168,169], a phenotype that can be mimicked by
Dax-1 overexpression in transgenic mice with a poor Sry
allele [170]. DAX-1 mutations in humans are responsible
for adrenal hypoplasia congenita as well as
hypogonadotrophic hypogonadism suggesting that DAX-
1 may perform similar functions as SF-1 [171]. Indeed, SF-
1 and Dax-1 are coexpressed in steroidogenic tissues as
well as in the VMH and pituitary, early in development
[47,172,173]. However, when overexpressed in Y1 adren-
ocortical cells, DAX-1 markedly impairs steroidogenic
output and transcriptionaly represses the promoters of SF-
1 target genes such as StAR, P450scc, 3β-HSD [174,175]
and akr1-b7 [92]. Essentially two mechanisms have been
proposed for DAX-1 mediated transcriptional repression,
although they are probably not mutually exclusive. DAX-
1 can repress SF-1 target genes expression either by bind-
ing DNA to hairpin-like structures [176], or by physically
interacting with SF-1, independently of the DNA context
[107]. This interaction implies a carboxy-terminal repres-
sion domain (437 to 447) and a proximal interaction
domain of SF-1 (226 to 230) [152] (figure 1) that contact
amino-terminal LXXLL domains of DAX-1 [151,177]. This
physical interaction allows the recruitment of the core-
pressors NcoR [152] and Alien [178] to SF-1-responsive
genes promoters. The physiological relevance of such a
negative functional interaction between Dax-1 and SF-1 is
as yet unclear as Dax-1 knock-out in mice does not lead to
marked adrenal defects [179]. However, it is noteworthy
Table 3: Transcription factors or cofactors that interact with SF-1. For each interacting factor, the resulting functional interaction, the 
experimental approach used to evidence the physical interaction and the model promoter are indicated.
Factor Functional interaction Physical interaction Promoter Bibliography
TreP132 allows CBP/p300 recruitment Co-IP, pull-down, two-hybrid P450scc [160,161]
GATA-4 Independent of GATA binding to DNA Pull-down MIS [106,150]
SOX9 Increases transcription in the presence of SF-1 Two-hybrid, pull-down, co-IP, EMSA MIS [105]
WT1-KTS Activation by WT-1 is dependent on SF-1 binding to its site. No 
WT-1 binding to DNA
Two-hybrid, GST pull-down MIS [107]
Sp1 Cooperation dependent on the cell type Co-IP, two-hybrid, EMSA StAR [202]
Sp1 Cooperation required for basal and cAMP-induced activity. Allows 
recruitment of CBP
Two-hybrid, EMSA bovine P450scc [153,162]
Egr-1 Synergistic activation. Egr-1 expression is induced by GnRH. Pull-down LH-β [155–157]
Ptx-1 Synergy depends on SF-1 binding to DNA Pull-down, two-hybrid LH-β [158,159]
CREB Synergy in basal and cAMP-induced conditions. Allows CBP 
recuitment
Pull-down α-Inhibin [163]
CREB Synergy in response to cAMP. FSH induces CREB and SF-1 
phosphorylation
Not demonstrated Aromatase [86,164]
AP-1/c-jun Synergy for P450scc and an artificial promoter activation Pull-down P450scc and SFRE-tk-CAT [14,21]
TF-IIB No determined Pull-down [14]
C/EBPβ C/EBP binding sites are required for activation by SF-1 Pull-down mStAR [112]
USF USF is required for SF-1 to activate rFSH-R promoter. Activation 
is inhibited by PKA.
Not demonstrated rFSH-R [209]
AR AR represses LHβ transcription by interacting with SF-1 Pull-down bLHβ [154]
DP103 Inhibits SF-1 transcriptional activity by interacting with a proximal 
repression domain.
Co-IP, pull-down P450scc, P450c21, 
progesterone production
[148,149]
P54nrb et PSF Repression of basal and induced hCYP17 promoter activity EMSA, co-IP hCYP17 [222]
WT1 Aromatase transcription inhibition. Integrity of the SFRE is 
required
Not demonstrated Aromatase [223]
DAX-1 Inhibits SF-1 transcriptional activity NCoR/Alien recruitment Pull-down, two-hybrid Synthetic promoters and SF-1 
target genes
[107,151,15
2]Nuclear Receptor 2003, 1 http://www.nuclear-receptor.com/content/1/1/8
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that Dax-1 ablation in SF-1 haploinsufficient mice allows
a reversion of the histological and functional adrenal
defects, suggesting that the two receptors interact in vivo
[180]. Furthermore, we have been able to observe Dax-1
downregulation in either ACTH-treated mice or adreno-
cortical ATC-1 cells that naturally express Dax-1, indicat-
ing that this receptor may be implicated in hormonal
responsiveness in vivo (B. Ragazzon, personal
communication).
An unexpected repressor of SF-1 activity is the androgen
receptor. The increase in plasmatic LH concentrations
which is induced by GnRH leads to increased sex steroid
production by the gonads. In turn, sex steroids exert a
negative feedback on GnRH and LH synthesis (figure 6).
Recently, Jorgensen and Nilson, have elegantly demon-
strated that androgen receptor was able to repress LH-β
promoter transactivation by interacting with SF-1 LBD
[154]. Under low GnRH conditions, AR blocks the func-
tional interaction between SF-1 and Ptx1/Egr-1. When
GnRH concentrations in pituitary gonadotropes increase,
Egr-1 expression is induced [156] and allows recruitment
of Ptx-1 as well as AR displacement, resulting in the for-
mation of an activating complex composed of SF-1, Egr-1
and Ptx1. When circulating androgens increase, activated
AR displaces Egr-1 and Ptx1, thus repressing LH-β tran-
scription in response to SF-1 [154]. This model (figure 6)
perfectly illustrates the complex interactions that are
required fo SF-1 target genes activation. It is likely that
such mechanisms may participate to the control of SF-1
target genes expression in response to cAMP increases.
Post-translationnal SF-1 alterations
Although it is clear that SF-1 transcriptional activity
requires complex interactions with numerous cofactors,
the mechanisms underlying the recruitment of these part-
ners are still unclear. Because PKA is implicated in the
stimulation of most of SF-1 target genes expression, its
role in SF-1 activity has been extensively investigated. In
vivo, SF-1 is phosphorylated in response to granulosa cells
stimulation by FSH [86]. In vitro, PKA can phosphorylate
SF-1 LBD and N-terminal region [101,135]. Although SF-
1 seems to be implicated in the cAMP responsiveness of
the rat CYP17 gene, its in vitro phosphorylation by PKA
decreases its DNA binding capacity, an observation which
is not compatible with its activating role [101,135]. In
heterologous cell systems SF-1 is phosphorylated on ser-
ine 203 by the MAPK ERK2, regardless of the presence of
cAMP. This residue is situated in the proximal activation
domain, the integrity of which is essential for SF-1 activity.
Serine 203 phosphorylation is required for SF-1
transcriptional activity and allows the recruitment of two
cofactors, the coactivator GRIP1/TIF2 and the corepressor
SMRT [25]. Recently, Desclozeaux et al., have shown that
SF-1 hinge and helix 1 of the LBD were able to set helices
2 to 12 of the LBD in an active conformation reminiscent
of ligand-activated nuclear receptors, albeit in the absence
of a ligand. Helices 2 to 12 recruitment is enhanced by
MAPK stimulation and decreased by mutating serine 203,
or in the presence of MKP-1, a MAPK specific phos-
phatase. At last, serine 203 phosphorylation stabilizes SF-
1 LBD, an observation reminiscent of ligand-activated
nuclear receptors [18]. This shows that apart from being
implicated in cofactor recruitment [25] serine 203 phos-
phorylation also structures and stabilizes SF-1 LBD. How-
ever, these experiments do not establish a link between
cAMP stimulation and SF-1 activity. This may depend on
activation of the MAPK pathway by PKA [181]. Indeed,
cAMP-induced StAR transcription is dependent on activa-
tion of the MPAK pathway in Y1 and MA-10 cells. This
activation induces SF-1 phosphorylation in vivo in Y1
cells, resulting in an increase in SF-1 binding in EMSA
[182]. However, cAMP-induced P450scc expression does
not seem to depend on MAPK activation in the same
experiments [182]. Furthermore, cAMP pathway stimula-
tion in H295 cells results in a decrease in SF-1 overall
phosphorylation [183], indicating that PKA/MAPK
crossovers may be gene and cell-specific. Thus in H295
cells, MAPK inhibition by the specific inhibitor PD98059
does not reduce, but on the contrary, stimulates hCYP17
transcription [183]. Indeed, StAR and hCYP17 cAMP-
stimulated transcription in H295 cells is dependent on
protein phosphatase activities [183,184]. In H295 cells,
MKP-1 that can be phosphorylated by PKA in vitro, is
overexpressed in response to cAMP stimulation. MKP-1
overexpression leads to an increase in hCYP17 expression,
whereas MKP-1 inhibition by an antisense RNA prevents
hCYP17 induction by cAMP. Whether MKP-1 is directly
implicated in SF-1 activity is still unclear. However, it is
noteworthy that phosphatase inhibitors decrease SF-1
transcriptionnal activity on the hCYP17 promoter, indi-
cating that at least one phosphatase is required for pro-
moter activation by SF-1 [185].
Altogether, these results seem rather contradictory.
Although it is probable that the MAPK pathway influences
SF-1 activity, it is still unclear whether this implicates
direct phosphorylation of SF-1 by a MAPK. Also, it seems
that such a mechanism would not necessarily apply to all
cell types or promoters. One pitfall of these experiments is
that the MAPK pathway is highly sensitive to extracellular
changes and temporal variations in the experimental set-
ting. Completely different experimental conditions may
thus account for the contradictory observations. At last,
future experiments may distinguish between overall SF-1
phosphorylation and phosphorylation on specific resi-
dues such as serine 203. When these mechanisms are
decyphered, it will be interesting to study the effect of one
particular phosphorylation or dephosphorylation on theNuclear Receptor 2003, 1 http://www.nuclear-receptor.com/content/1/1/8
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recruitment of cofactors such as p/CIP versus  TIF2 in
response to cAMP stimulation.
Another emerging activation control mechanism for
nuclear receptors is their acetylation [186]. SF-1 is
acetylated in vivo in a heterologous cell system and inter-
A model for LHβ promoter repression by a physical interaction between AR and SF-1 Figure 6
A model for LHβ promoter repression by a physical interaction between AR and SF-1. (After Jorgensen and Nil-
son, Ref. [201]) In the presence of elevated androgen concentrations, AR (androgen receptor) interacts with SF-1 on LHβ pro-
moter, preventing interaction of Egr-1 with its response elements. LHβ is then turned off. A GnRH pulse (resulting from a 
reduction in circulating androgen concentrations), favours Egr-1 transcription, increasing its accumulation. In turn, Egr-1 dis-
places AR from SF-1 and favours an active setting of transcription factors on LHβ promoter. LHβ transcription is then trig-
gered. The resulting LH protein production in turn stimulates androgens production by the gonads.Nuclear Receptor 2003, 1 http://www.nuclear-receptor.com/content/1/1/8
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acts with the acetyl-transferase GCN5, which can acetylate
SF-1 in vitro. Although SF-1-dependent activation of a
reporter gene may depend on SF-1 acetylation in the pres-
ence of GCN5, experimental results obtained by mutating
the potential acetylation sites or by the use of the deacety-
lase inhibitor trichostatin A, are contradictory [147]. If
more substantial data is obtained regarding the role of
acetylation on SF-1 activity, it will be interesting to study
the implication of certain histone acetyl transferase (HAT)
coactivators such as CBP/p300, in SF-1 acetylation in vivo.
Conclusions
A key role for SF-1, in the differentiation and the mainte-
nance of the differentiated function of the gonads,
adrenals and particular regions of the pituitary and
hypothalamus is now clearly established (table 1). Its
targets implicated in the maintenance of the differentiated
function of steroidogenic tissues and in sex determination
are now, at least in part, identified. Tissue-specific SF-1
knock-out at late developmental stages or at adulthood
(when differentiated function is established) may confirm
the results of transient transfections and may allow the
identification of new SF-1 targets.
Although tremendous progress has been accomplished
since SF-1 cloning, major questions remain unanswered.
Indeed, genes whose down-regulation (or up-regulation)
in SF-1 null mice may account for the regression of
gonadal, adrenal and VMH anlages are still unidentified.
Another important issue is the identification of the mech-
anisms that allow activation of this orphan nuclear recep-
tor at certain stages during embryonic and post-natal
development or in response to external stimuli such as
increased cAMP concentrations evoked by trophic
hormones in their target tissues. Recent results of our
group show that a SF-1 binding site is dispensable at birth
for akr1-b7 promoter activity but is required 20 days later
[42]. On the contrary, Hoyle et al., show that a SF-1 bind-
ing site is required for early developmental expression of
DAX-1, but is dispensable after birth [187]. Forthcoming
studies will require a careful evaluation of the distinct
roles of SF-1 during early development and after birth.
Competing interests
None declared.
Authors' Contributions
P.V. wrote this article as part of is thesis manuscript.
A.M. and A-M. L-M. are P.V. PhD supervisors. They helped
him with writing this manuscript.
G.V. is the head of the PCEM team.
References
1. Morohashi K, Honda S, Inomata Y, Handa H and Omura T: A com-
mon trans-acting factor, Ad4-binding protein, to the pro-
moters of steroidogenic P-450s. J Biol Chem 1992, 267:17913-9.
2. Rice DA, Mouw AR, Bogerd AM and Parker KL: A shared pro-
moter element regulates the expression of three steroidog-
enic enzymes. Mol Endocrinol 1991, 5:1552-61.
3. Honda S, Morohashi K, Nomura M, Takeya H, Kitajima M and Omura
T: Ad4BP regulating steroidogenic P-450 gene is a member
of steroid hormone receptor superfamily. J Biol Chem 1993,
268:7494-502.
4. Lavorgna G, Karim FD, Thummel CS and Wu C: Potential role for
a FTZ-F1 steroid receptor superfamily member in the con-
trol of Drosophila metamorphosis. Proc Natl Acad Sci U S A 1993,
90:3004-8.
5. Laudet V: Evolution of the nuclear receptor superfamily: early
diversification from an ancestral orphan receptor.  J Mol
Endocrinol 1997, 19:207-26.
6. De Mendonca RL, Bouton D, Bertin B, Escriva H, Noel C, Vanacker
JM, Cornette J, Laudet V and Pierce RJ: A functionally conserved
member of the FTZ-F1 nuclear receptor family from Schis-
tosoma mansoni. Eur J Biochem 2002, 269:5700-11.
7. Kotomura N, Ninomiya Y, Umesono K and Niwa O: Transcrip-
tional regulation by competition between ELP isoforms and
nuclear receptors. Biochem Biophys Res Commun 1997, 230:407-12.
8. Ninomiya Y, Okada M, Kotomura N, Suzuki K, Tsukiyama T and Niwa
O: Genomic organization and isoforms of the mouse ELP
gene. J Biochem (Tokyo) 1995, 118:380-9.
9. Luo X, Ikeda Y, Schlosser DA and Parker KL: Steroidogenic factor
1 is the essential transcript of the mouse Ftz-F1 gene. Mol
Endocrinol 1995, 9:1233-9.
10. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umes-
ono K, Blumberg B, Kastner P, Mark M and Chambon P et al.: The
nuclear receptor superfamily: the second decade. Cell 1995,
83:835-9.
11. Hammer GD and Ingraham HA: Steroidogenic factor-1: its role
in endocrine organ development and differentiation.  Front
Neuroendocrinol 1999, 20:199-223.
12. Wilson TE, Fahrner TJ and Milbrandt J: The orphan receptors
NGFI-B and steroidogenic factor 1 establish monomer bind-
ing as a third paradigm of nuclear receptor-DNA
interaction. Mol Cell Biol 1993, 13:5794-804.
13. Nitta M, Ku S, Brown C, Okamoto AY and Shan B: CPF: an orphan
nuclear receptor that regulates liver-specific expression of
the human cholesterol 7alpha-hydroxylase gene.  Proc Natl
Acad Sci U S A 1999, 96:6660-5.
14. Li LA, Chiang EF, Chen JC, Hsu NC, Chen YJ and Chung BC: Func-
tion of steroidogenic factor 1 domains in nuclear localiza-
tion, transactivation, and interaction with transcription
factor TFIIB and c-Jun. Mol Endocrinol 1999, 13:1588-98.
15. Achermann JC, Ozisik G, Ito M, Orun UA, Harmanci K, Gurakan B
and Jameson JL: Gonadal determination and adrenal develop-
ment are regulated by the orphan nuclear receptor ster-
oidogenic factor-1, in a dose-dependent manner.  J Clin
Endocrinol Metab 2002, 87:1829-33.
16. Mellon SH and Bair SR: 25-Hydroxycholesterol is not a ligand
for the orphan nuclear receptor steroidogenic factor-1 (SF-
1). Endocrinology 1998, 139:3026-9.
17. Giguere V: Orphan nuclear receptors: from gene to function.
Endocr Rev 1999, 20:689-725.
18. Desclozeaux M, Krylova IN, Horn F, Fletterick RJ and Ingraham HA:
Phosphorylation and intramolecular stabilization of the lig-
and binding domain in the nuclear receptor steroidogenic
factor 1. Mol Cell Biol 2002, 22:7193-203.
19. Ito M, Yu RN and Jameson JL: Steroidogenic factor-1 contains a
carboxy-terminal transcriptional activation domain that
interacts with steroid receptor coactivator-1. Mol Endocrinol
1998, 12:290-301.
20. Crawford PA, Polish JA, Ganpule G and Sadovsky Y: The activation
function-2 hexamer of steroidogenic factor-1 is required, but
not sufficient for potentiation by SRC-1. Mol Endocrinol 1997,
11:1626-35.
21. Li LA, Lala D and Chung BC: Function of steroidogenic factor 1
(SF1) ligand-binding domain in gene activation and interac-
tion with AP1. Biochem Biophys Res Commun 1998, 250:318-20.Nuclear Receptor 2003, 1 http://www.nuclear-receptor.com/content/1/1/8
Page 18 of 23
(page number not for citation purposes)
22. Shao D, Rangwala SM, Bailey ST, Krakow SL, Reginato MJ and Lazar
MA: Interdomain communication regulating ligand binding
by PPAR-gamma. Nature 1998, 396:377-80.
23. He B and Wilson EM: The NH(2)-terminal and carboxyl-termi-
nal interaction in the human androgen receptor. Mol Genet
Metab 2002, 75:293-8.
24. He B, Bowen NT, Minges JT and Wilson EM: Androgen-induced
NH2- and COOH-terminal Interaction Inhibits p160 coacti-
vator recruitment by activation function 2. J Biol Chem 2001,
276:42293-301.
25. Hammer GD, Krylova I, Zhang Y, Darimont BD, Simpson K, Weigel
NL and Ingraham HA: Phosphorylation of the nuclear receptor
SF-1 modulates cofactor recruitment: integration of hor-
mone signaling in reproduction and stress.  Mol Cell 1999,
3:521-6.
26. Ikeda Y, Shen WH, Ingraham HA and Parker KL: Developmental
expression of mouse steroidogenic factor-1, an essential reg-
ulator of the steroid hydroxylases.  Mol Endocrinol 1994,
8:654-62.
27. Hatano O, Takayama K, Imai T, Waterman MR, Takakusu A, Omura
T and Morohashi K: Sex-dependent expression of a transcrip-
tion factor, Ad4BP, regulating steroidogenic P-450 genes in
the gonads during prenatal and postnatal rat development.
Development 1994, 120:2787-97.
28. Hatano O, Takakusu A, Nomura M and Morohashi K: Identical ori-
gin of adrenal cortex and gonad revealed by expression pro-
files of Ad4BP/SF-1. Genes Cells 1996, 1:663-71.
29. Sadovsky Y, Crawford PA, Woodson KG, Polish JA, Clements MA,
Tourtellotte LM, Simburger K and Milbrandt J: Mice deficient in the
orphan receptor steroidogenic factor 1 lack adrenal glands
and gonads but express P450 side-chain-cleavage enzyme in
the placenta and have normal embryonic serum levels of
corticosteroids. Proc Natl Acad Sci U S A 1995, 92:10939-43.
30. Ikeda Y, Lala DS, Luo X, Kim E, Moisan MP and Parker KL: Charac-
terization of the mouse FTZ-F1 gene, which encodes a key
regulator of steroid hydroxylase gene expression.  Mol
Endocrinol 1993, 7:852-60.
31. Ramayya MS, Zhou J, Kino T, Segars JH, Bondy CA and Chrousos GP:
Steroidogenic factor 1 messenger ribonucleic acid expres-
sion in steroidogenic and nonsteroidogenic human tissues:
Northern blot and in situ hybridization studies. J Clin Endocrinol
Metab 1997, 82:1799-806.
32. Ben-Zimra M, Koler M and Orly J: Transcription of cholesterol
side-chain cleavage cytochrome P450 in the placenta: acti-
vating protein-2 assumes the role of steroidogenic factor-1
by binding to an overlapping promoter element. Mol Endocrinol
2002, 16:1864-80.
33. Ingraham HA, Lala DS, Ikeda Y, Luo X, Shen WH, Nachtigal MW,
Abbud R, Nilson JH and Parker KL: The nuclear receptor ster-
oidogenic factor 1 acts at multiple levels of the reproductive
axis. Genes Dev 1994, 8:2302-12.
34. Shinoda K, Lei H, Yoshii H, Nomura M, Nagano M, Shiba H, Sasaki H,
Osawa Y, Ninomiya Y and Niwa O et al.: Developmental defects
of the ventromedial hypothalamic nucleus and pituitary
gonadotroph in the Ftz-F1 disrupted mice.  Dev Dyn 1995,
204:22-9.
35. Ikeda Y, Luo X, Abbud R, Nilson JH and Parker KL: The nuclear
receptor steroidogenic factor 1 is essential for the formation
of the ventromedial hypothalamic nucleus. Mol Endocrinol 1995,
9:478-86.
36. Patel MV, McKay IA and Burrin JM: Transcriptional regulators of
steroidogenesis, DAX-1 and SF-1, are expressed in human
skin. J Invest Dermatol 2001, 117:1559-65.
37. Courchay G, Boyera N, Bernard BA and Mahe Y: Messenger RNA
expression of steroidogenesis enzyme subtypes in the
human pilosebaceous unit. Skin Pharmacol 1996, 9:169-76.
38. Slominski A, Ermak G and Mihm M: ACTH receptor, CYP11A1,
CYP17 and CYP21A2 genes are expressed in skin. J Clin Endo-
crinol Metab 1996, 81:2746-9.
39. Venencie PY, Meduri G, Pissard S, Jolivet A, Loosfelt H, Milgrom E and
Misrahi M: Luteinizing hormone/human chorionic gonado-
trophin receptors in various epidermal structures.  Br J
Dermatol 1999, 141:438-46.
40. Morohashi K, Tsuboi-Asai H, Matsushita S, Suda M, Nakashima M, Sas-
ano H, Hataba Y, Li CL, Fukata J and Irie J et al.: Structural and
functional abnormalities in the spleen of an mFtz-F1 gene-
disrupted mouse. Blood 1999, 93:1586-94.
41. Wotus C, Levay-Young BK, Rogers LM, Gomez-Sanchez CE and
Engeland WC: Development of adrenal zonation in fetal rats
defined by expression of aldosterone synthase and 11b-
hydroxylase. Endocrinology 1998, 139:4397-4403.
42. Martinez A, Val P, Sahut-Barnola I, Aigueperse C, Veyssiere G and
Lefrancois Martinez AM: SF-1 controls the aldose reductase
akr1b7 gene promoter in transgenic mice through an atypi-
cal binding site. Endocrinology 2003, 144:2111-2120.
43. Okimoto DK, Blaus A, Schmidt M, Gordon MK, Dent GW and Levine
S: Differential expression of c-fos and tyrosine hydroxylase
mRNA in the adrenal gland of the infant rat: evidence for an
adrenal hyporesponsive period.  Endocrinology 2002,
143:1717-25.
44. Hanley NA, Ball SG, Clement-Jones M, Hagan DM, Strachan T, Lind-
say S, Robson S, Ostrer H, Parker KL and Wilson DI: Expression of
steroidogenic factor 1 and Wilms' tumour 1 during early
human gonadal development and sex determination. Mech
Dev 1999, 87:175-80.
45. de Santa Barbara P, Moniot B, Poulat F and Berta P: Expression and
subcellular localization of SF-1, SOX9, WT1, and AMH pro-
teins during early human testicular development. Dev Dyn
2000, 217:293-8.
46. Mesiano S and Jaffe RB: Role of growth factors in the develop-
mental regulation of the human fetal adrenal cortex. Steroids
1997, 62:62-72.
47. Hanley NA, Rainey WE, Wilson DI, Ball SG and Parker KL: Expres-
sion profiles of SF-1, DAX1, and CYP17 in the human fetal
adrenal gland: potential interactions in gene regulation. Mol
Endocrinol 2001, 15:57-68.
48. Roselli CE, Jorgensen EZ, Doyle MW and Ronnekleiv OK: Expres-
sion of the orphan receptor steroidogenic factor-1 mRNA in
the rat medial basal hypothalamus. Brain Res Mol Brain Res 1997,
44:66-72.
49. Stallings NR, Hanley NA, Majdic G, Zhao L, Bakke M and Parker KL:
Development of a transgenic green fluorescent protein line-
age marker for steroidogenic factor 1.  Endocr Res 2002,
28:497-504.
50. Luo X, Ikeda Y and Parker KL: A cell-specific nuclear receptor is
essential for adrenal and gonadal development and sexual
differentiation. Cell 1994, 77:481-90.
51. Dellovade TL, Young M, Ross EP, Henderson R, Caron K, Parker K
and Tobet SA: Disruption of the gene encoding SF-1 alters the
distribution of hypothalamic neuronal phenotypes.  J Comp
Neurol 2000, 423:579-89.
52. Majdic G, Young M, Gomez-Sanchez E, Anderson P, Szczepaniak LS,
Dobbins RL, McGarry JD and Parker KL: Knockout mice lacking
steroidogenic factor 1 are a novel genetic model of hypotha-
lamic obesity. Endocrinology 2002, 143:607-14.
53. Zhao L, Bakke M, Krimkevich Y, Cushman LJ, Parlow AF, Camper SA
and Parker KL: Steroidogenic factor 1 (SF1) is essential for
pituitary gonadotrope function. Development 2001, 128:147-54.
54. Zhao L, Bakke M and Parker KL: Pituitary-specific knockout of
steroidogenic factor 1. Mol Cell Endocrinol 2001, 185:27-32.
55. Zhao L, Bakke M, Krimkevich Y, Cushman LJ, Parlow AF, Camper SA
and Parker KL: Hypomorphic phenotype in mice with pitui-
tary-specific knockout of steroidogenic factor 1. Genesis 2001,
30:65-9.
56. Barnhart KM and Mellon PL: The orphan nuclear receptor, ster-
oidogenic factor-1, regulates the glycoprotein hormone
alpha-subunit gene in pituitary gonadotropes. Mol Endocrinol
1994, 8:878-85.
57. Halvorson LM, Kaiser UB and Chin WW: Stimulation of luteiniz-
ing hormone beta gene promoter activity by the orphan
nuclear receptor, steroidogenic factor-1.  J Biol Chem 1996,
271:6645-50.
58. Keri RA and Nilson JH: A steroidogenic factor-1 binding site is
required for activity of the luteinizing hormone beta subunit
promoter in gonadotropes of transgenic mice.  J Biol Chem
1996, 271:10782-5.
59. Brown P and McNeilly AS: Steroidogenic factor-1 (SF-1) and the
regulation of expression of luteinising hormone and follicle
stimulating hormone b-subunits in the sheep anterior pitui-
tary in vivo. Int J Biochem Cell Biol 1997, 29:1513-24.Nuclear Receptor 2003, 1 http://www.nuclear-receptor.com/content/1/1/8
Page 19 of 23
(page number not for citation purposes)
60. Levallet J, Koskimies P, Rahman N and Huhtaniemi I: The promoter
of murine follicle-stimulating hormone receptor: functional
characterization and regulation by transcription factor ster-
oidogenic factor 1. Mol Endocrinol 2001, 15:80-92.
61. Pincas H, Laverriere JN and Counis R: Pituitary adenylate cyclase-
activating polypeptide and cyclic adenosine 3',5'-monophos-
phate stimulate the promoter activity of the rat gonadotro-
pin-releasing hormone receptor gene via a bipartite
response element in gonadotrope-derived cells. J Biol Chem
2001, 276:23562-71.
62. Pincas H, Amoyel K, Counis R and Laverriere JN: Proximal cis-act-
ing elements, including steroidogenic factor 1, mediate the
efficiency of a distal enhancer in the promoter of the rat
gonadotropin-releasing  hormone receptor gene.  Mol
Endocrinol 2001, 15:319-37.
63. Ngan ES, Cheng PK, Leung PC and Chow BK: Steroidogenic fac-
tor-1 interacts with a gonadotrope-specific element within
the first exon of the human gonadotropin-releasing hor-
mone receptor gene to mediate gonadotrope-specific
expression. Endocrinology 1999, 140:2452-62.
64. Kendall SK, Saunders TL, Jin L, Lloyd RV, Glode LM, Nett TM, Keri
RA, Nilson JH and Camper SA: Targeted ablation of pituitary
gonadotropes in transgenic mice.  Mol Endocrinol 1991,
5:2025-36.
65. Brobeck JR: Mechanism of the development of obesity in ani-
mals with hypothalamic lesions. Physiol Rev 1946, 26:541-559.
66. LeCouter J, Kowalski J, Foster J, Hass P, Zhang Z, Dillard-Telm L,
Frantz G, Rangell L, DeGuzman L and Keller GA et al.: Identification
of an angiogenic mitogen selective for endocrine gland
endothelium. Nature 2001, 412:877-84.
67. Achermann JC, Ito M, Hindmarsh PC and Jameson JL: A mutation in
the gene encoding steroidogenic factor-1 causes XY sex
reversal and adrenal failure in humans.  Nat Genet 1999,
22:125-6.
68. Biason-Lauber A and Schoenle EJ: Apparently normal ovarian dif-
ferentiation in a prepubertal girl with transcriptionally inac-
tive steroidogenic factor 1 (NR5A1/SF-1) and adrenocortical
insufficiency. Am J Hum Genet 2000, 67:1563-8.
69. Bland ML, Jamieson CA, Akana SF, Bornstein SR, Eisenhofer G, Dall-
man MF and Ingraham HA: Haploinsufficiency of steroidogenic
factor-1 in mice disrupts adrenal development leading to an
impaired stress response.  Proc Natl Acad Sci U S A 2000,
97:14488-93.
70. Lu TT, Makishima M, Repa JJ, Schoonjans K, Kerr TA, Auwerx J and
Mangelsdorf DJ: Molecular basis for feedback regulation of bile
acid synthesis by nuclear receptors. Mol Cell 2000, 6:507-15.
71. Wang ZN, Bassett M and Rainey WE: Liver receptor homologue-
1 is expressed in the adrenal and can regulate transcription
of 11 beta-hydroxylase. J Mol Endocrinol 2001, 27:255-8.
72. Falender AE, Lanz R, Malenfant D, Belanger L and Richards JS: Differ-
ential expression of steroidogenic factor-1 and FTF/LRH-1 in
the rodent ovary. Endocrinology 2003, 144:3598-3610.
73. Sirianni R, Seely JB, Attia G, Stocco DM, Carr BR, Pezzi V and Rainey
WE: Liver receptor homologue-1 is expressed in human ster-
oidogenic tissues and activates transcription of genes encod-
ing steroidogenic enzymes. J Endocrinol 2002, 174:R13-7.
74. Crawford PA, Sadovsky Y and Milbrandt J: Nuclear receptor ster-
oidogenic factor 1 directs embryonic stem cells toward the
steroidogenic lineage. Mol Cell Biol 1997, 17:3997-4006.
75. Beuschlein F, Mutch C, Bavers DL, Ulrich-Lai YM, Engeland WC,
Keegan C and Hammer GD: Steroidogenic factor-1 is essential
for compensatory adrenal growth following unilateral
adrenalectomy. Endocrinology 2002, 143:3122-35.
76. Bicknell AB, Lomthaisong K, Woods RJ, Hutchinson EG, Bennett HP,
Gladwell RT and Lowry PJ: Characterization of a serine pro-
tease that cleaves pro-gamma-melanotropin at the adrenal
to stimulate growth. Cell 2001, 105:903-12.
77. Kelman Z: PCNA: structure, functions and interactions. Onco-
gene 1997, 14:629-40.
78. Bassett MH, Zhang Y, Clyne C, White PC and Rainey WE: Differen-
tial regulation of aldosterone synthase and 11beta-hydroxy-
lase transcription by steroidogenic factor-1. J Mol Endocrinol
2002, 28:125-35.
79. Hu MC, Hsu NC, Pai CI, Wang CK and Chung B: Functions of the
upstream and proximal steroidogenic factor 1 (SF-1)-bind-
ing sites in the CYP11A1 promoter in basal transcription and
hormonal response. Mol Endocrinol 2001, 15:812-8.
80. Gizard F, El-Alfy M, Duguay Y, Lavallee B, DeWitte F, Staels B, Beatty
BG and Hum DW: Function of the transcriptional regulating
protein of 132 kDa (TReP-132) on human P450scc gene
expression. Endocr Res 2002, 28:559-74.
81. Wang XL, Bassett M, Zhang Y, Yin S, Clyne C, White PC and Rainey
WE: Transcriptional regulation of human 11beta-hydroxy-
lase (hCYP11B1). Endocrinology 2000, 141:3587-94.
82. Sewer MB and Waterman MR: Transcriptional complexes at the
CYP17 CRS. Endocr Res 2002, 28:551-8.
83. Jacob AL and Lund J: Mutations in the activation function-2 core
domain of steroidogenic factor-1 dominantly suppresses
PKA-dependent transactivation of the bovine CYP17 gene. J
Biol Chem 1998, 273:13391-4.
84. Bakke M and Lund J: Mutually exclusive interactions of two
nuclear orphan receptors determine activity of a cyclic ade-
nosine 3',5'-monophosphate-responsive sequence in the
bovine CYP17 gene. Mol Endocrinol 1995, 9:327-39.
85. Michael MD, Kilgore MW, Morohashi K and Simpson ER: Ad4BP/
SF-1 regulates cyclic AMP-induced transcription from the
proximal promoter (PII) of the human aromatase P450
(CYP19) gene in the ovary. J Biol Chem 1995, 270:13561-6.
86. Carlone DL and Richards JS: Functional interactions, phosphor-
ylation, and levels of 3',5'-cyclic adenosine monophosphate-
regulatory element binding protein and steroidogenic fac-
tor-1 mediate hormone-regulated and constitutive expres-
sion of aromatase in gonadal cells.  Mol Endocrinol 1997,
11:292-304.
87. Pfeifer SM, Furth EE, Ohba T, Chang YJ, Rennert H, Sakuragi N, Bill-
heimer JT and Strauss JF 3rd: Sterol carrier protein 2: a role in
steroid hormone synthesis?  J Steroid Biochem Mol Biol 1993,
47:167-72.
88. Stocco DM: Intramitochondrial cholesterol transfer. Biochim
Biophys Acta 2000, 1486:184-97.
89. Mascaro C, Nadal A, Hegardt FG, Marrero PF and Haro D: Contri-
bution of steroidogenic factor 1 to the regulation of choles-
terol synthesis. Biochem J 2000, 350(Pt 3):785-90.
90. Martinez A, Val P, Jean C, Veyssiere G and Lefrancois-Martinez AM:
SF-1 controls the expression of the scavenger gene akr1b7:
in vitro and in vivo approaches. Endocr Res 2002, 28:515-8.
91. Val P, Aigueperse C, Lefrancois-Martinez AM, Jean C, Veyssiere G and
Martinez A: Role of three SF-1 binding sites in the expression
of the mvdp/akr1-b7 isocaproaldehyde reductase in Y1 cells.
Endocr Res 2002, 28:527-33.
92. Aigueperse C, Val P, Pacot C, Darne C, Lalli E, P Sassone-Corsi, Vey-
ssiere G, Jean C and Martinez A: SF-1 (steroidogenic factor-1), C/
EBPbeta (CCAAT/enhancer binding protein), and ubiqui-
tous transcription factors NF1 (nuclear factor 1) and Sp1
(selective promoter factor 1) are required for regulation of
the mouse aldose reductase-like gene (AKR1B7) expression
in adrenocortical cells. Mol Endocrinol 2001, 15:93-111.
93. Lefrancois-Martinez AM, Tournaire C, Martinez A, Berger M, Daou-
dal S, Tritsch D, Veyssiere G and Jean C: Product of side-chain
cleavage of cholesterol, isocaproaldehyde, is an endogenous
specific substrate of mouse vas deferens protein, an aldose
reductase-like protein in adrenocortical cells. J Biol Chem 1999,
274:32875-80.
94. Chinn AM, Ciais D, Bailly S, Chambaz E, LaMarre J and Feige JJ: Iden-
tification of two novel ACTH-responsive genes encoding
manganese-dependent superoxide dismutase (SOD2) and
the zinc finger protein TIS11b [tetradecanoyl phorbol ace-
tate (TPA)-inducible sequence 11b].  Mol Endocrinol 2002,
16:1417-27.
95. McCann SM, Haens G, Mastronardi C, Walczewska A, Karanth S, Ret-
tori V and Yu WH: The Role of Nitric Oxide (NO) in Control
of LHRH Release that Mediates Gonadotropin Release and
Sexual Behavior. Curr Pharm Des 2003, 9:381-90.
9 6 . W e i  X ,  S a s a k i  M ,  H u a n g  H ,  D a w s o n  V L  a n d  D a w s o n  T M :  The
orphan nuclear receptor, steroidogenic factor 1, regulates
neuronal nitric oxide synthase gene expression in pituitary
gonadotropes. Mol Endocrinol 2002, 16:2828-39.
97. Ando H, Hew CL and Urano A: Signal transduction pathways
and transcription factors involved in the gonadotropin-
releasing hormone-stimulated gonadotropin subunit geneNuclear Receptor 2003, 1 http://www.nuclear-receptor.com/content/1/1/8
Page 20 of 23
(page number not for citation purposes)
expression.  Comp Biochem Physiol B Biochem Mol Biol 2001,
129:525-32.
98. Swain A and Lovell-Badge R: Mammalian sex determination: a
molecular drama. Genes Dev 1999, 13:755-67.
99. Albrecht KH and Eicher EM: Evidence that Sry is expressed in
pre-Sertoli cells and Sertoli and granulosa cells have a com-
mon precursor. Dev Biol 2001, 240:92-107.
100. Swain A and Lovell-Badge R: Sex determination and
differentiation. In: Mouse Development 2002, 17:371-393.
101. de Santa Barbara P, Mejean C, Moniot B, Malcles MH, Berta P and
Boizet-Bonhoure B: Steroidogenic factor-1 contributes to the
cyclic-adenosine monophosphate down-regulation of human
SRY gene expression. Biol Reprod 2001, 64:775-83.
102. Pilon N, Daneau I, Paradis V, Hamel F, Lussier JG, Viger RS and Silver-
sides DW: Porcine SRY Promoter Is a Target for Steroidog-
enic Factor 1. Biol Reprod 2003, 68:1098-106.
103. Capel B: Sex in the 90s: SRY and the switch to the male
pathway. Annu Rev Physiol 1998, 60:497-523.
104. Shen WH, Moore CC, Ikeda Y, Parker KL and Ingraham HA:
Nuclear receptor steroidogenic factor 1 regulates the mulle-
rian inhibiting substance gene: a link to the sex determina-
tion cascade. Cell 1994, 77:651-61.
105. De Santa Barbara P, Bonneaud N, Boizet B, Desclozeaux M, Moniot
B, Sudbeck P, Scherer G, Poulat F and Berta P: Direct interaction
of SRY-related protein SOX9 and steroidogenic factor 1 reg-
ulates transcription of the human anti-Mullerian hormone
gene. Mol Cell Biol 1998, 18:6653-65.
106. Tremblay JJ and Viger RS: Transcription factor GATA-4
enhances Mullerian inhibiting substance gene transcription
through a direct interaction with the nuclear receptor SF-1.
Mol Endocrinol 1999, 13:1388-401.
107. Nachtigal MW, Hirokawa Y, Enyeart-VanHouten DL, Flanagan JN,
Hammer GD and Ingraham HA: Wilms' tumor 1 and Dax-1 mod-
ulate the orphan nuclear receptor SF-1 in sex-specific gene
expression. Cell 1998, 93:445-54.
108. Arango NA, Lovell-Badge R and Behringer RR: Targeted mutagen-
esis of the endogenous mouse Mis gene promoter: in vivo
definition of genetic pathways of vertebrate sexual
development. Cell 1999, 99:409-19.
109. Zimmermann S, Schwarzler A, Buth S, Engel W and Adham IM: Tran-
scription of the Leydig insulin-like gene is mediated by ster-
oidogenic factor-1. Mol Endocrinol 1998, 12:706-13.
110. Koskimies P, Levallet J, Sipila P, Huhtaniemi I and Poutanen M:
Murine relaxin-like factor promoter: functional characteri-
zation and regulation by transcription factors steroidogenic
factor 1 and DAX-1. Endocrinology 2002, 143:909-19.
111. Amsterdam A, Tajima K and Sasson R: Cell-specific regulation of
apoptosis by glucocorticoids: implication to their anti-
inflammatory action. Biochem Pharmacol 2002, 64:843-50.
112. Reinhart AJ, Williams SC, Clark BJ and Stocco DM: SF-1 (steroidog-
enic factor-1) and C/EBP beta (CCAAT/enhancer binding
protein-beta) cooperate to regulate the murine StAR (ster-
oidogenic acute regulatory) promoter.  Mol Endocrinol 1999,
13:729-41.
113. Hasegawa T, Zhao L, Caron KM, Majdic G, Suzuki T, Shizawa S, Sas-
ano H and Parker KL: Developmental roles of the steroidogenic
acute regulatory protein (StAR) as revealed by StAR knock-
out mice. Mol Endocrinol 2000, 14:1462-71.
114. Hu MC, Hsu NC, El Hadj NB, Pai C, Chu HP, Wang CK and Chung
BC: Steroid deficiency syndromes in mice with targeted dis-
ruption of Cyp11a1. Mol Endocrinol 2002, 16:1943-50.
115. Yaswen L, Diehl N, Brennan MB and Hochgeschwender U: Obesity
in the mouse model of pro-opiomelanocortin deficiency
responds to peripheral melanocortin. Nat Med 1999, 5:1066-70.
116. Bicknell AB and Lowry PJ: Adrenal growth is controlled by
expression of specific pro-opiomelanocortin serine protease
in the outer adrenal cortex. Endocr Res 2002, 28:589-95.
117. Pignatelli D, Ferreira J, Vendeira P, Magalhaes MC and Vinson GP:
Proliferation of capsular stem cells induced by ACTH in the
rat adrenal cortex. Endocr Res 2002, 28:683-91.
118. Bicknell AB: Identification of a receptor for N-POMC peptides.
Endocr Res 2002, 28:309-14.
119. Lala DS, Syka PM, Lazarchik SB, Mangelsdorf DJ, Parker KL and Hey-
man RA: Activation of the orphan nuclear receptor steroidog-
enic factor 1 by oxysterols.  Proc Natl Acad Sci U S A 1997,
94:4895-900.
120. Woodson KG, Crawford PA, Sadovsky Y and Milbrandt J: Charac-
terization of the promoter of SF-1, an orphan nuclear recep-
tor required for adrenal and gonadal development.  Mol
Endocrinol 1997, 11:117-26.
121. Scherrer SP, Rice DA and Heckert LL: Expression of steroidog-
enic factor 1 in the testis requires an interactive array of ele-
ments within its proximal promoter.  Biol Reprod 2002,
67:1509-21.
122. Nomura M, Bartsch S, Nawata H, Omura T and Morohashi K: An E
box element is required for the expression of the ad4bp
gene, a mammalian homologue of ftz-f1 gene, which is essen-
tial for adrenal and gonadal development. J Biol Chem 1995,
270:7453-61.
123. Harris AN and Mellon PL: The basic helix-loop-helix, leucine
zipper transcription factor, USF (upstream stimulatory fac-
tor), is a key regulator of SF-1 (steroidogenic factor-1) gene
expression in pituitary gonadotrope and steroidogenic cells.
Mol Endocrinol 1998, 12:714-26.
124. Oba K, Yanase T, Ichino I, Goto K, Takayanagi R and Nawata H:
Transcriptional regulation of the human FTZ-F1 gene
encoding Ad4BP/SF-1. J Biochem (Tokyo) 2000, 128:517-28.
125. Nomura M, Nawata H and Morohashi K: Autoregulatory loop in
the regulation of the mammalian ftz-f1 gene. J Biol Chem 1996,
271:8243-9.
126. Zubair M, Oka S, Ishihara S and Morohashi K: Analysis of Ad4BP/
SF-1 gene regulatory region. Endocr Res 2002, 28:535.
127. Quaggin SE, Schwartz L, Cui S, Igarashi P, Deimling J, Post M and Ros-
sant J: The basic-helix-loop-helix protein pod1 is critically
important for kidney and lung organogenesis.  Development
1999, 126:5771-83.
128. Tamura M, Kanno Y, Chuma S, Saito T and Nakatsuji N: Pod-1/Cap-
sulin shows a sex- and stage-dependent expression pattern in
the mouse gonad development and represses expression of
Ad4BP/SF-1. Mech Dev 2001, 102:135-44.
129. Kent J, Wheatley SC, Andrews JE, Sinclair AH and Koopman P: A
male-specific role for SOX9 in vertebrate sex
determination. Development 1996, 122:2813-22.
130. Shen JH and Ingraham HA: Regulation of the orphan nuclear
receptor steroidogenic factor 1 by Sox proteins. Mol Endocrinol
2002, 16:529-40.
131. Viger RS, Mertineit C, Trasler JM and Nemer M: Transcription fac-
tor GATA-4 is expressed in a sexually dimorphic pattern
during mouse gonadal development and is a potent activator
of the Mullerian inhibiting substance promoter. Development
1998, 125:2665-75.
132. Tremblay JJ and Viger RS: GATA factors differentially activate
multiple gonadal promoters through conserved GATA reg-
ulatory elements. Endocrinology 2001, 142:977-86.
133. Nomura M, Kawabe K, Matsushita S, Oka S, Hatano O, Harada N,
Nawata H and Morohashi K: Adrenocortical and gonadal
expression of the mammalian Ftz-F1 gene encoding Ad4BP/
SF-1 is independent of pituitary control. J Biochem (Tokyo) 1998,
124:217-24.
134. Crawford PA, Sadovsky Y, Woodson K, Lee SL and Milbrandt J:
Adrenocortical function and regulation of the steroid 21-
hydroxylase gene in NGFI-B-deficient mice. Mol Cell Biol 1995,
15:4331-16.
135. P Zhang and Mellon SH: The orphan nuclear receptor ster-
oidogenic factor-1 regulates the cyclic adenosine 3',5'-mono-
phosphate-mediated transcriptional activation of rat
cytochrome P450c17 (17 alpha-hydroxylase/c17-20 lyase).
Mol Endocrinol 1996, 10:147-58.
136. Mamluk R, Greber Y and Meidan R: Hormonal regulation of mes-
senger ribonucleic acid expression for steroidogenic factor-
1, steroidogenic acute regulatory protein, and cytochrome
P450 side-chain cleavage in bovine luteal cells.  Biol Reprod
1999, 60:628-34.
137. Aesoy R, Mellgren G, Morohashi K and Lund J: Activation of cAMP-
dependent protein kinase increases the protein level of ster-
oidogenic factor-1. Endocrinology 2002, 143:295-303.
138. Chau YM, Crawford PA, Woodson KG, Polish JA, Olson LM and
Sadovsky Y: Role of steroidogenic-factor 1 in basal and 3',5'-
cyclic adenosine monophosphate-mediated regulation of
cytochrome P450 side-chain cleavage enzyme in the mouse.
Biol Reprod 1997, 57:765-71.Nuclear Receptor 2003, 1 http://www.nuclear-receptor.com/content/1/1/8
Page 21 of 23
(page number not for citation purposes)
139. Enyeart JJ, Boyd RT and Enyeart JA: ACTH and AII differentially
stimulate steroid hormone orphan receptor mRNAs in adre-
nal cortical cells. Mol Cell Endocrinol 1996, 124:97-110.
140. Hosokawa K, Dantes A, C Schere-Levy, Barash A, Yoshida Y, Kotsuji
F, Vlodavsky I and Amsterdam A: Induction of Ad4BP/SF-1, ster-
oidogenic acute regulatory protein, and cytochrome
P450scc enzyme system expression in newly established
human granulosa cell lines. Endocrinology 1998, 139:4679-87.
141. Sahut-Barnola I, Lefrancois-Martinez AM, Jean C, Veyssiere G and
Martinez A: Adrenal tumorigenesis targeted by the cortico-
tropin-regulated promoter of the aldo-keto reductase
AKR1B7 gene in transgenic mice. Endocr Res 2000, 26:885-98.
142. Sugawara T, Abe S, Sakuragi N, Fujimoto Y, Nomura E, Fujieda K,
Saito M and Fujimoto S: RIP 140 modulates transcription of the
steroidogenic acute regulatory protein gene through inter-
actions with both SF-1 and DAX-1.  Endocrinology 2001,
142:3570-7.
143. Zhou D, Quach KM, Yang C, Lee SY, Pohajdak B and Chen S: PNRC:
a proline-rich nuclear receptor coregulatory protein that
modulates transcriptional activation of multiple nuclear
receptors including orphan receptors SF1 (steroidogenic
factor 1) and ERRalpha1 (estrogen related receptor alpha-1).
Mol Endocrinol 2000, 14:986-98.
144. Zhou D and Chen S: PNRC2 is a 16 kDa coactivator that inter-
acts with nuclear receptors through an SH3-binding motif.
Nucleic Acids Res 2001, 29:3939-48.
145. Kabe Y, Goto M, Shima D, Imai T, Wada T, Morohashi K, Shirakawa
M, Hirose S and Handa H: The role of human MBF1 as a tran-
scriptional coactivator. J Biol Chem 1999, 274:34196-202.
146. Borud B, Hoang T, Bakke M, Jacob AL, Lund J and Mellgren G: The
nuclear receptor coactivators p300/CBP/cointegrator-asso-
ciated protein (p/CIP) and transcription intermediary factor
2 (TIF2) differentially regulate PKA-stimulated transcrip-
tional activity of steroidogenic factor 1. Mol Endocrinol 2002,
16:757-73.
147. Jacob AL, Lund J, Martinez P and Hedin L: Acetylation of ster-
oidogenic factor 1 protein regulates its transcriptional activ-
ity and recruits the coactivator GCN5.  J Biol Chem 2001,
276:37659-64.
148. Yan X, Mouillet JF, Ou Q and Sadovsky Y: A novel domain within
the DEAD-box protein DP103 is essential for transcriptional
repression and helicase activity. Mol Cell Biol 2003, 23:414-23.
149. Ou Q, Mouillet JF, Yan X, Dorn C, Crawford PA and Sadovsky Y: The
DEAD box protein DP103 is a regulator of steroidogenic
factor-1. Mol Endocrinol 2001, 15:69-79.
150. Watanabe K, Clarke TR, Lane AH, Wang X and Donahoe PK:
Endogenous expression of Mullerian inhibiting substance in
early postnatal rat sertoli cells requires multiple steroidog-
enic factor-1 and GATA-4-binding sites. Proc Natl Acad Sci U S A
2000, 97:1624-9.
151. Ito M, Yu R and Jameson JL: DAX-1 inhibits SF-1-mediated
transactivation via a carboxy-terminal domain that is
deleted in adrenal hypoplasia congenita.  Mol Cell Biol 1997,
17:1476-83.
152. Crawford PA, Dorn C, Sadovsky Y and Milbrandt J: Nuclear recep-
tor DAX-1 recruits nuclear receptor corepressor N-CoR to
steroidogenic factor 1. Mol Cell Biol 1998, 18:2949-56.
153. Liu Z and Simpson ER: Molecular mechanism for cooperation
between Sp1 and steroidogenic factor-1 (SF-1) to regulate
bovine CYP11A gene expression.  Mol Cell Endocrinol 1999,
153:183-96.
154. Jorgensen JS and Nilson JH: AR suppresses transcription of the
LHbeta subunit by interacting with steroidogenic factor-1.
Mol Endocrinol 2001, 15:1505-16.
155. Halvorson LM, Ito M, Jameson JL and Chin WW: Steroidogenic fac-
tor-1 and early growth response protein 1 act through two
composite DNA binding sites to regulate luteinizing hor-
mone beta-subunit gene expression.  J Biol Chem 1998,
273:14712-20.
156. Tremblay JJ and Drouin J: Egr-1 is a downstream effector of
GnRH and synergizes by direct interaction with Ptx1 and SF-
1 to enhance luteinizing hormone beta gene transcription.
Mol Cell Biol 1999, 19:2567-76.
157. Kaiser UB, Halvorson LM and Chen MT: Sp1, steroidogenic factor
1 (SF-1), and early growth response protein 1 (egr-1) binding
sites form a tripartite gonadotropin-releasing hormone
response element in the rat luteinizing hormone-beta gene
promoter: an integral role for SF-1.  Mol Endocrinol 2000,
14:1235-45.
158. Tremblay JJ, Lanctot C and Drouin J: The pan-pituitary activator
of transcription, Ptx1 (pituitary homeobox 1), acts in syn-
ergy with SF-1 and Pit1 and is an upstream regulator of the
Lim-homeodomain gene Lim3/Lhx3.  Mol Endocrinol 1998,
12:428-41.
159. Tremblay JJ, Marcil A, Gauthier Y and Drouin J: Ptx1 regulates SF-
1 activity by an interaction that mimics the role of the ligand-
binding domain. Embo J 1999, 18:3431-41.
160. Gizard F, Lavallee B, DeWitte F, Teissier E, Staels B and Hum DW:
The transcriptional regulating protein of 132 kDa (TReP-
132) enhances P450scc gene transcription through interac-
tion with steroidogenic factor-1 in human adrenal cells. J Biol
Chem 2002, 277:39144-55.
161. Gizard F, Lavallee B, DeWitte F and Hum DW: A novel zinc finger
protein TReP-132 interacts with CBP/p300 to regulate
human CYP11A1 gene expression.  J Biol Chem 2001,
276:33881-33892.
162. Liu Z and Simpson ER: Steroidogenic factor 1 (SF-1) and SP1
are required for regulation of bovine CYP11A gene expres-
sion in bovine luteal cells and adrenal Y1 cells. Mol Endocrinol
1997, 11:127-37.
163. Ito M, Park Y, Weck J, Mayo KE and Jameson JL: Synergistic activa-
tion of the inhibin alpha-promoter by steroidogenic factor-1
and cyclic adenosine 3',5'-monophosphate. Mol Endocrinol 2000,
14:66-81.
164. Carlone DL and Richards JS: Evidence that functional interac-
tions of CREB and SF-1 mediate hormone regulated expres-
sion of the aromatase gene in granulosa cells and
constitutive expression in R2C cells. J Steroid Biochem Mol Biol
1997, 61:223-31.
165. Chan HM and La Thangue NB: p300/CBP proteins: HATs for
transcriptional bridges and scaffolds.  J Cell Science 2001,
114:2363-2373.
166. Muscatelli F, Strom TM, Walker AP, Zanaria E, Recan D, Meindl A,
Bardoni B, Guioli S, Zehetner G and Rabl W et al.: Mutations in the
DAX-1 gene give rise to both X-linked adrenal hypoplasia
congenita and hypogonadotropic hypogonadism. Nature 1994,
372:672-6.
167. Zanaria E, Muscatelli F, Bardoni B, Strom TM, Guioli S, Guo W, Lalli
E, Moser C, Walker AP and McCabe ER et al.: An unusual member
of the nuclear hormone receptor superfamily responsible for
X-linked adrenal hypoplasia congenita.  Nature 1994,
372:635-41.
168. Bardoni B, Zanaria E, Guioli S, Floridia G, Worley KC, Tonini G, Fer-
rante E, Chiumello G, McCabe ER and Fraccaro M et al.: A dosage
sensitive locus at chromosome Xp21 is involved in male to
female sex reversal. Nat Genet 1994, 7:497-501.
169. Zanaria E, Bardoni B, Dabovic B, Calvari V, Fraccaro M, Zuffardi O
and Camerino G: Xp duplications and sex reversal. Philos Trans R
Soc Lond B Biol Sci 1995, 350:291-6.
170. Swain A, Narvaez V, Burgoyne P, Camerino G and Lovell-Badge R:
Dax1 antagonizes Sry action in mammalian sex
determination. Nature 1998, 391:761-7.
171. Achermann JC, Meeks JJ and Jameson JL: Phenotypic spectrum of
mutations in DAX-1 and SF-1.  Mol Cell Endocrinol 2001,
185:17-25.
172. Swain A, Zanaria E, Hacker A, Lovell-Badge R and Camerino G:
Mouse Dax1 expression is consistent with a role in sex deter-
mination as well as in adrenal and hypothalamus function.
Nat Genet 1996, 12:404-9.
173. Ikeda Y, Swain A, Weber TJ, Hentges KE, Zanaria E, Lalli E, Tamai KT,
Sassone-Corsi P, Lovell-Badge R and Camerino G et al.: Steroidog-
enic factor 1 and Dax-1 colocalize in multiple cell lineages:
potential links in endocrine development. Mol Endocrinol 1996,
10:1261-72.
174. Lalli E, Bardoni B, Zazopoulos E, Wurtz JM, Strom TM, Moras D and
Sassone-Corsi P: A transcriptional silencing domain in DAX-1
whose mutation causes adrenal hypoplasia congenita.  Mol
Endocrinol 1997, 11:1950-60.
175. Lalli E, Melner MH, Stocco DM and Sassone-Corsi P: DAX-1 blocks
steroid production at multiple levels.  Endocrinology 1998,
139:4237-43.Nuclear Receptor 2003, 1 http://www.nuclear-receptor.com/content/1/1/8
Page 22 of 23
(page number not for citation purposes)
176. Zazopoulos E, Lalli E, Stocco DM and Sassone-Corsi P: DNA bind-
ing and transcriptional repression by DAX-1 blocks
steroidogenesis. Nature 1997, 390:311-315.
177. Suzuki T, Kasahara M, Yoshioka H, Umesono K and Morohashi K:
LXXLL motifs in Dax-1 have target specificity for the orphan
nuclear receptors Ad4BP/SF-1 and LRH-1. Endocr Res 2002,
28:537.
178. Altincicek B, Tenbaum SP, Dressel U, Thormeyer D, Renkawitz R and
Baniahmad A: Interaction of the corepressor Alien with DAX-
1 is abrogated by mutations of DAX-1 involved in adrenal
hypoplasia congenita. J Biol Chem 2000, 275:7662-7.
179. Yu RN, Ito M, Saunders TL, Camper SA and Jameson JL: Role of
Ahch in gonadal development and gametogenesis. Nat Genet
1998, 20:353-7.
180. Babu PS, Bavers DL, Beuschlein F, Shah S, Jeffs B, Jameson JL and Ham-
mer GD: Interaction between Dax-1 and steroidogenic fac-
tor-1 in vivo: increased adrenal responsiveness to ACTH in
the absence of Dax-1. Endocrinology 2002, 143:665-73.
181. Richards JS: New signaling pathways for hormones and cyclic
adenosine 3',5'-monophosphate action in endocrine cells. Mol
Endocrinol 2001, 15:209-18.
182. Gyles SL, Burns CJ, Whitehouse BJ, Sugden D, Marsh PJ, Persaud SJ
and Jones PM: ERKs regulate cyclic AMP-induced steroid syn-
thesis through transcription of the steroidogenic acute reg-
ulatory (StAR) gene. J Biol Chem 2001, 276:34888-95.
183. Sewer MB and Waterman MR: Adrenocorticotropin/cyclic ade-
nosine 3',5'-monophosphate-mediated transcription of the
human CYP17 gene in the adrenal cortex is dependent on
phosphatase activity. Endocrinology 2002, 143:1769-77.
184. Jones PM, Sayed SB, Persaud SJ, Burns CJ, Gyles S and Whitehouse BJ:
Cyclic AMP-induced expression of steroidogenic acute regu-
latory protein is dependent upon phosphoprotein phos-
phatase activites. J Mol Endocrinol 2000, 24:233-239.
185. Sewer MB and Waterman MR: cAMP-dependent protein kinase
(PKA) enhances CYP17 transcription via MKP-1 activation
in H295R human adrenocortical cells. J Biol Chem 2002, 27:27.
186. Fu M, Wang C, Wang J, Zhang X, Sakamaki T, Yeung YG, Chang C,
Hopp T, Fuqua SA and Jaffray E et al.: Androgen receptor acetyla-
tion governs trans activation and MEKK1-induced apoptosis
without affecting in vitro sumoylation and trans-repression
function. Mol Cell Biol 2002, 22:3373-3388.
187. Hoyle C, Narvaez V, Alldus G, R Lovell-Badge and Swain A: Dax1
expression is dependent on steroidogenic factor 1 in the
developing gonad. Mol Endocrinol 2002, 16:747-56.
188. Clemens JW, Lala DS, Parker KL and Richards JS: Steroidogenic
factor-1 binding and transcriptional activity of the choles-
terol side-chain cleavage promoter in rat granulosa cells.
Endocrinology 1994, 134:1499-508.
189. Leers-Sucheta S, Morohashi K, Mason JI and Melner MH: Synergistic
activation of the human type II 3beta-hydroxysteroid dehy-
drogenase/delta5-delta4 isomerase promoter by the tran-
scription factor steroidogenic factor-1/adrenal 4-binding
protein and phorbol ester. J Biol Chem 1997, 272:7960-7.
190. Tee MK, Babalola GO, Aza-Blanc P, Speek M, Gitelman SE and Miller
WL: A promoter within intron 35 of the human C4A gene ini-
tiates abundant adrenal-specific transcription of a 1 kb RNA:
location of a cryptic CYP21 promoter element?  Hum Mol
Genet 1995, 4:2109-16.
191. Takayama K, Morohashi K, Honda S, Hara N and Omura T: Contri-
bution of Ad4BP, a steroidogenic cell-specific transcription
factor, to regulation of the human CYP11A and bovine
CYP11B genes through their distal promoters.  J Biochem
(Tokyo) 1994, 116:193-203.
192. Morohashi K, Zanger UM, Honda S, Hara M, Waterman MR and
Omura T: Activation of CYP11A and CYP11B gene promot-
ers by the steroidogenic cell-specific transcription factor,
Ad4BP. Mol Endocrinol 1993, 7:1196-204.
193. Lynch JP, Lala DS, Peluso JJ, Luo W, Parker KL and White BA: Ster-
oidogenic factor 1, an orphan nuclear receptor, regulates the
expression of the rat aromatase gene in gonadal tissues. Mol
Endocrinol 1993, 7:776-86.
194. Young M and McPhaul MJ: A steroidogenic factor-1-binding site
and cyclic adenosine 3',5'-monophosphate response ele-
ment-like elements are required for the activity of the rat
aromatase promoter in rat Leydig tumor cell lines. Endocrinol-
ogy 1998, 139:5082-93.
195. Cao G, Garcia CK, Wyne KL, Schultz RA, Parker KL and Hobbs HH:
Structure and localization of the human gene encoding SR-
BI/CLA-1. Evidence for transcriptional control by steroidog-
enic factor 1. J Biol Chem 1997, 272:33068-76.
196. Lopez D, Sandhoff TW and McLean MP: Steroidogenic factor-1
mediates cyclic 3',5'-adenosine monophosphate regulation
of the high density lipoprotein receptor. Endocrinology 1999,
140:3034-44.
197. Lopez D, Nackley AC, W Shea-Eaton, Xue J, Schimmer BP and
McLean MP: Effects of mutating different steroidogenic factor-
1 protein regions on gene regulation. Endocrine 2001, 14:353-62.
198. Lopez D, Shea-Eaton W, Sanchez MD and McLean MP: DAX-1
represses the high-density lipoprotein receptor through
interaction with positive regulators sterol regulatory ele-
ment-binding protein-1a and steroidogenic factor-1.  Endo-
crinology 2001, 142:5097-106.
199. Lopez D, Shea-Eaton W and McLean MP: Characterization of a
steroidogenic factor-1-binding site found in promoter of
sterol carrier protein-2 gene. Endocrine 2001, 14:253-61.
200. Sugawara T, Kiriakidou M, McAllister JM, Kallen CB and Strauss JF
3rd: Multiple steroidogenic factor 1 binding elements in the
human steroidogenic acute regulatory protein gene 5'-flank-
ing region are required for maximal promoter activity and
cyclic AMP responsiveness. Biochemistry 1997, 36:7249-55.
201. Sugawara T, Kiriakidou M, McAllister JM, Holt JA, Arakane F and
Strauss JF 3rd: Regulation of expression of the steroidogenic
acute regulatory protein (StAR) gene: a central role for ster-
oidogenic factor 1. Steroids 1997, 62:5-9.
202. Sugawara T, Saito M and Fujimoto S: Sp1 and SF-1 interact and
cooperate in the regulation of human steroidogenic acute
regulatory protein gene expression.  Endocrinology 2000,
141:2895-903.
203. Brand C, Nury D, Chambaz EM, Feige JJ and Bailly S: Transcrip-
tional regulation of the gene encoding the StAR protein in
the human adrenocortical cell line, H295R by cAMP and
TGFbeta1. Endocr Res 2000, 26:1045-53.
204. Sandhoff TW, Hales DB, Hales KH and McLean MP: Transcriptional
regulation of the rat steroidogenic acute regulatory protein
gene by steroidogenic factor 1. Endocrinology 1998, 139:4820-31.
205. Rust W, Stedronsky K, Tillmann G, Morley S, Walther N and Ivell R:
The role of SF-1/Ad4BP in the control of the bovine gene for
the steroidogenic acute regulatory (StAR) protein.  J Mol
Endocrinol 1998, 21:189-200.
206. Naville D, Penhoat A, Marchal R, Durand P and Begeot M: SF-1 and
the transcriptional regulation of the human ACTH receptor
gene. Endocr Res 1998, 24:391-5.
207. Naville D, Penhoat A, Durand P and Begeot M: Three steroidog-
enic factor-1 binding elements are required for constitutive
and cAMP-regulated expression of the human adrenocorti-
cotropin receptor gene.  Biochem Biophys Res Commun 1999,
255:28-33.
208. King PJ and Clark AJ: Analysis of the first exon of the murine
ACTH receptor gene. Endocr Res 1998, 24:397-402.
209. Heckert LL: Activation of the rat follicle-stimulating hormone
receptor promoter by steroidogenic factor 1 is blocked by
protein kinase a and requires upstream stimulatory factor
binding to a proximal E box element.  Mol Endocrinol 2001,
15:704-15.
210. Chen S, Shi H, Liu X and Segaloff DL: Multiple elements and pro-
tein factors coordinate the basal and cyclic adenosine 3',5'-
monophosphate-induced transcription of the lutropin recep-
tor gene in rat granulosa cells. Endocrinology 1999, 140:2100-9.
211. Duval DL, Nelson SE and Clay CM: A binding site for steroidog-
enic factor-1 is part of a complex enhancer that mediates
expression of the murine gonadotropin-releasing hormone
receptor gene. Biol Reprod 1997, 56:160-8.
212. Duval DL, Nelson SE and Clay CM: The tripartite basal enhancer
of the gonadotropin-releasing hormone (GnRH) receptor
gene promoter regulates cell-specific expression through a
novel GnRH receptor activating sequence. Mol Endocrinol 1997,
11:1814-21.
213. Dorn C, Ou Q, Svaren J, Crawford PA and Sadovsky Y: Activation
of luteinizing hormone beta gene by gonadotropin-releasing
hormone requires the synergy of early growth response-1
and steroidogenic factor-1. J Biol Chem 1999, 274:13870-6.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Nuclear Receptor 2003, 1 http://www.nuclear-receptor.com/content/1/1/8
Page 23 of 23
(page number not for citation purposes)
214. Halvorson LM, Kaiser UB and Chin WW: The protein kinase C
system acts through the early growth response protein 1 to
increase LHbeta gene expression in synergy with steroidog-
enic factor-1. Mol Endocrinol 1999, 13:106-16.
215. Fowkes RC, King P and Burrin JM: Regulation of human glycopro-
tein hormone alpha-subunit gene transcription in LbetaT2
gonadotropes by protein kinase C and extracellular signal-
regulated kinase 1/2. Biol Reprod 2002, 67:725-34.
216. Wehrenberg U, Ivell R, Jansen M, von Goedecke S and Walther N:
Two orphan receptors binding to a common site are
involved in the regulation of the oxytocin gene in the bovine
ovary. Proc Natl Acad Sci U S A 1994, 91:1440-4.
217. Wehrenberg U, von Goedecke S, Ivell R and Walther N: The
orphan receptor SF-1 binds to the COUP-like element in the
promoter of the actively transcribed oxytocin gene.  J
Neuroendocrinol 1994, 6:1-4.
218. Hu Z, Zhuang L, Guan X, Meng J and Dufau ML: Steroidogenic fac-
tor-1 is an essential transcriptional activator for gonad-spe-
cific expression of promoter I of the rat prolactin receptor
gene. J Biol Chem 1997, 272:14263-71.
219. Burris TP, Guo W, Le T and McCabe ER: Identification of a puta-
tive steroidogenic factor-1 response element in the DAX-1
promoter. Biochem Biophys Res Commun 1995, 214:576-81.
220. Vilain E, Guo W, Zhang YH and McCabe ER: DAX1 gene expres-
sion upregulated by steroidogenic factor 1 in an adrenocor-
tical carcinoma cell line. Biochem Mol Med 1997, 61:1-8.
221. Yu RN, Ito M and Jameson JL: The murine Dax-1 promoter is
stimulated by SF-1 (steroidogenic factor-1) and inhibited by
COUP-TF (chicken ovalbumin upstream promoter-tran-
scription factor) via a composite nuclear receptor-regula-
tory element. Mol Endocrinol 1998, 12:1010-22.
222. Sewer MB, Nguyen VQ, Huang CJ, Tucker PW, Kagawa N and
Waterman MR: Transcriptional activation of human CYP17 in
H295R adrenocortical cells depends on complex formation
among p54(nrb)/NonO, protein-associated splicing factor,
and SF-1, a complex that also participates in repression of
transcription. Endocrinology 2002, 143:1280-90.
223. Gurates B, Sebastian S, Yang S, Zhou J, Tamura M, Fang Z, Suzuki T,
Sasano H and Bulun SE: WT1 and DAX-1 inhibit aromatase
P450 expression in human endometrial and endometriotic
stromal cells. J Clin Endocrinol Metab 2002, 87:4369-77.